National Institute for Health and Care Excellence

Final

Colorectal cancer (update)

[D4] Local and systemic treatments for metastatic colorectal cancer isolated in the peritoneum

NICE guideline NG151 Evidence reviews January 2020

Final

Developed by the National Guideline Alliance part of the Royal College of Obstetricians and Gynaecologists



FINAL

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2020. All rights reserved. Subject to Notice of Rights.

ISBN: 978-1-4731-3657-1

Contents

Contents	4
Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum	6
Review question	6
Introduction	6
Summary of the protocol	6
Methods and process	7
Clinical evidence	7
Summary of clinical studies included in the evidence review	7
Quality assessment of clinical outcomes included in the evidence review	8
Economic evidence	8
Economic model	8
Evidence statements	9
The committee's discussion of the evidence	10
References	12
Appendices	
Appendix A – Review protocol	14
Review protocol for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	14
Appendix B – Literature search strategies	18
Literature search strategies for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	
Appendix C – Clinical evidence study selection	21
Clinical study selection for: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	21
Appendix D – Clinical evidence tables	
Clinical evidence tables for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	22
Appendix E – Forest plots	29
Forest plots for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	29
Appendix F – GRADE tables	31
GRADE tables for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	
Appendix G – Economic evidence study selection	
Tresser e	

Economic evidence study selection for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	35
Appendix H – Economic evidence tables	36
Economic evidence tables for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	36
Appendix I – Economic evidence profiles	37
Economic evidence profiles for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	37
Appendix J – Economic analysis	38
Economic evidence analysis for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	. 38
Appendix K – Excluded studies	39
Excluded clinical studies for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	39
Appendix L – Research recommendations	48
Research recommendations for review question: What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?	48

Optimal combination and sequence of

2 local and systemic treatments in patients

3 presenting with metastatic colorectal

4 cancer isolated in the peritoneum

5 This evidence review supports recommendation 1.5.9.

6 Review question

7 What is the optimal combination and sequence of local and systemic treatments in patients8 presenting with metastatic colorectal cancer isolated in the peritoneum?

9 Introduction

- 10 Peritoneal carcinomatosis from colorectal cancer is the second-most common cause of death
- 11 from colorectal cancer after liver metastases. Palliative systemic chemotherapy has
- 12 commonly been used in an attempt to prolong survival for patients with peritoneal
- 13 carcinomatosis. Efforts to achieve long-term survival have seen the combined use of
- 14 cytoreductive surgery (CRS) to remove the metastases and heated intraperitoneal
- 15 chemotherapy (HIPEC) to eradicate the residual disease. However, CRS with HIPEC is
- 16 associated with high rates of morbidity and treatment-related mortality (Mehta 2016; Verwaal
- 17 2003). Therefore, the aim of this review was to determine the most effective combination and
- 18 sequence of treatments in patients presenting with metastatic colorectal cancer in the
- 19 peritoneum that is potentially curable with local treatments such as CRS and HIPEC.

20 Summary of the protocol

Please see Table 1 for a summary of the population, intervention, comparison and outcomes
 (PICO) characteristics of this review.

23 Table 1: Summary of the protocol (PICO table)

Table 1. Summary of the protocol (FICO table)			
Population	Adults with colorectal cancer with metastases isolated in the peritoneum.		
	Subgroups:		
	 Symptomatic or asymptomatic primary colorectal tumour 		
	 Synchronous or metachronous metastases 		
Intervention	Cytoreductive surgery (CRS)		
	 CRS with hyperthermic intraperitoneal chemotherapy (HIPEC) 		
	 Systemic anti-cancer therapy (SACT) alone 		
Comparison	 Individual interventions or combinations of interventions compared to each other 		
	Best supportive care		
Outcomes	Critical		
	 Progression-free survival 		
	Overall survival		
	Overall quality of life		
	Important		

• Treatment-related mortality

- Any grade 3 or 4 complications
- Length of hospital stay

For further details see the review protocol in appendix A. 1

2 Methods and process

- 3 This evidence review was developed using the methods and process described in
- Developing NICE guidelines: the manual 2014. Methods specific to this review question are 4
- described in the review protocol in appendix A. 5
- 6 Declarations of interest were recorded according to NICE's 2014 conflicts of interest policy
- until 31 March 2018. From 1 April 2018, declarations of interest were recorded according to 7
- NICE's 2018 conflicts of interest policy. Those interests declared until April 2018 were 8
- reclassified according to NICE's 2018 conflicts of interest policy (see Register of Interests). 9

10 Clinical evidence

11 Included studies

- Two randomised controlled trials (RCTs) and 1 observational study (4 publications) were 12
- included in this review (PRODIGE 7 [Quenet 2016]; van Oudheusden 2015; Verwaal 2003 13 14 [Verwaal 2008]).
- 15 The included studies are summarised in Table 2.
- 16 One RCT compared CRS + HIPEC + oxaliplatin to CRS only (PRODIGE 7 [Quenet 2016])
- 17 and the other RCT compared CRS + HIPEC + SACT to surgery + SACT (Verwaal 2003;
- Verwaal 2008). The observational study compared chemotherapy (with or without 18
- Bevacizumab) to supportive care (van Oudheusden 2015). 19
- 20 See the literature search strategy in appendix B and study selection flow chart in appendix C.

21 Excluded studies

22 Studies not included in this review with reasons for their exclusions are provided in appendix 23 K.

24 Summary of clinical studies included in the evidence review

25 Summaries of the studies that were included in this review are presented in Table 2.

Table 2: Summary of included studies 26

Study	Population	Intervention/Compari son	Outcomes
Comparison 1: CRS with	th HIPEC versus CRS +/	- SACT	
PRODIGE 7 (Quenet 2016) Multi-centre RCT France	N=264 patients aged 18-70 with histopathologically confirmed colorectal cancer; peritoneal carcinoma extension ≤ 25 (Sugarbaker Index, determined intra operatively).	CRS + HIPEC + oxaliplatin versus CRS alone	 Overall survival Treatment-related mortality Grade 3 or 4 complications

FINAL

Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

Study	Population	Intervention/Compari son	Outcomes
Comparison 1: CRS wi	th HIPEC versus CRS +/	- SACT	
Verwaal 2003; Verwaal 2008	N=105 patients with histologically proven peritoneal metastases	CRS + HIPEC + SACT versus standard surgery and	 Overall survival Treatment-related mortality
Single-centre RCT	of colorectal adenocarcinoma or positive cytology of	chemotherapy.	monanty
Netherlands	ascites.		
Comparison 2: SACT versus supportive care			
van Oudheusden 2015	N=186 patients with metachronous	Systemic treatment versus no systemic	Overall survival
Retrospective cohort study	peritoneal carcinomatosis of colorectal origin.	treatment.	
Netherlands			

1 CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; N: number; RCT: randomised 2 controlled trial; SACT: systemic anti-cancer therapy

3 See the full evidence tables in appendix D. No meta-analysis was conducted (and so there

4 are no forest plots in appendix E).

5 Quality assessment of clinical outcomes included in the evidence review

6 See the clinical evidence profiles in appendix F.

7 Economic evidence

8 Included studies

9 A systematic review of the economic literature was conducted but no economic studies were 10 identified which were applicable to this review question.

11 Excluded studies

- 12 A global search of economic evidence was undertaken for all review questions in this
- 13 guideline. See Supplement 2 for further information.

14 Economic model

- 15 No economic modelling was undertaken for this review because the committee agreed that
- 16 other topics were higher priorities for economic evaluation.

1 Evidence statements

2 Clinical evidence statements

3 Comparison 1: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal 4 chemotherapy (HIPEC) versus CRS +/- systemic anti-cancer therapy (SACT)

5 **Critical outcomes**

6 **Progression-free survival**

7 No evidence was identified to inform this outcome.

8 Overall survival

- Low quality evidence from 1 RCT (N=265; median follow-up 64 months) showed no
 clinically important difference in 5-year overall survival between those receiving CRS +
 HIPEC + oxaliplatin compared to those receiving CRS alone.
- Very low quality evidence from 1 RCT (N=105; median follow-up 22 months) showed a clinically important increase in 2 year overall survival between those receiving CRS + HIPEC + SACT compared to those receiving surgery + SACT.

15 **Overall quality of life**

16 No evidence was identified to inform this outcome.

17 Important outcomes

18 Treatment-related mortality

- Low quality evidence from 1 RCT (N=265) showed no clinically important difference in 30day treatment-related mortality between those receiving CRS + HIPEC + oxaliplatin compared to those receiving CRS alone.
- Very low quality evidence from 1 RCT (N=105) showed no clinically important difference in
 30-day treatment-related mortality between those receiving CRS + HIPEC + SACT
 compared to those receiving surgery + SACT.

25 Any grade 3 or 4 complications

Low quality evidence from 1 RCT (N=265) showed a clinically important increase in grade
 3 or 4 complications between those receiving CRS + HIPEC + oxaliplatin compared to
 those receiving CRS alone.

29 Length of hospital stay

30 No evidence was identified to inform this outcome.

31 Comparison 2: Systemic anti-cancer therapy (SACT) versus supportive care

32 Critical outcomes

33 Progression free survival

34 No evidence was identified to inform this outcome.

1 Overall survival

- Very low quality evidence from 1 retrospective cohort study (N=186) showed a clinically important increase in 50-month overall survival between those receiving SACT (chemotherapy alone) compared to those receiving supportive care.
- Very low quality evidence from 1 retrospective cohort study (N=186) showed a clinically important increase in 50-month overall survival between those receiving SACT
 (chemotherapy + bevacizumab) compared to those receiving supportive care.

8 **Overall quality of life**

9 No evidence was identified to inform this outcome.

10 Important outcomes

11 Treatment-related mortality

12 No evidence was identified to inform this outcome.

13 Any grade 3 or 4 complications

14 No evidence was identified to inform this outcome.

15 Length of hospital stay

16 No evidence was identified to inform this outcome.

17 Economic evidence statements

18 No economic evidence was identified which was applicable to this review question.

19 The committee's discussion of the evidence

20 Interpreting the evidence

21 The outcomes that matter most

- Progression-free survival, overall survival, and overall quality of life were considered critical outcomes for decision making because progression of the metastases suggests ineffective treatment, potentially requiring further treatment and affecting overall survival. Quality of life was a critical outcome because of the impact that different treatment options can have on
- 26 patients' functioning and the potential long term adverse effects.
- 27 Treatment-related mortality, grade 3 or 4 complications, and length of hospital stay were
- identified as important outcomes because they are indicative of the short-term side effects of
- 29 treatment.

30 The quality of the evidence

- 31 Evidence was available from 1 RCT comparing CRS + HIPEC + SACT to surgery + SACT, 1
- 32 RCT comparing CRS + HIPEC + oxaliplatin to CRS only and 1 observational study which
- compared chemotherapy (with or without bevacizumab) to supportive care without anysystemic therapy.
- 35 Evidence was available for overall survival, any grade 3 or 4 complications and treatment-
- 36 related mortality. The evidence was assessed using GRADE and varied from very low to low
- 37 quality. The quality of evidence was downgraded because of methodological limitations
- 38 affecting the risk of bias and imprecision in the risk estimate.

- 1 Methodological limitations affecting the risk of bias were due to a lack of information
- 2 regarding certain details such as randomisation, allocation methods, and outcomes
- 3 measured. One study failed to report the number of patients randomised; another reported
- 4 high levels of attrition; and another reported differences between the two groups at baseline.
- Indirectness was also an issue as three studies included patients with appendiceal disease;
 and in two of these studies, protocol violations also occurred.
- 7 Uncertainty around the risk estimate was generally attributable to low event rates and small8 sample sizes.

9 Benefits and harms

- 10 Despite the low quality of the evidence, it showed SACT to be beneficial in terms of overall 11 survival. Offering SACT is also current practice. Based on the clinical evidence and their 12 clinical expertise, the committee decided that SACT should be offered to patients with 13 colorectal cancer with isolated peritoneal metastases.
- 14 Evidence for CRS and HIPEC were more mixed. In the PRODIGE 7 trial (Quenet 2018),
- 15 overall survival rates for all patients were higher than expected (both arms received CRS),
- 16 which the committee interpreted as evidence that high quality surgery is beneficial for
- 17 survival outcomes. Additionally, the evidence indicated that there could be some benefit in
- 18 overall survival for those whose treatment included CRS, HIPEC and SACT. Receiving active
- 19 treatment, as opposed to supportive care increases the chance for survival. However, there
- 20 are also risks of mortality and morbidity that are associated with surgical interventions.
- The committee noted that the doses of oxaliplatin used in the PRODIGE 7 trial are much 21 higher than those used in the UK and could explain the high level of toxicity in the treatment 22 arm (CRS + HIPEC + oxaliplatin vs CRS alone). While lower doses of oxaliplatin are used in 23 the UK, this drug still has a risk of severe toxicity. The committee were aware of non-24 randomised evidence (Prada-Villeverde 2014) that compared CRS + HIPEC (mitomvcin C) 25 versus CRS + HIPEC (oxaliplatin) that found that there was no statistically significant 26 difference between groups in terms of median overall survival and that effectiveness of 27 28 regimens with oxaliplatin was linked to the patient's Peritoneal Surface Disease Severity 29 Score (PSDSS).
- Based on the evidence and their clinical expertise, the committee decided that a referral to a
 nationally commissioned specialist centre where CRS with HIPEC could be considered
 should be discussed within a multidisciplinary team. The committee made the
- recommendation in line with the NICE interventional procedure guidance (IPG331) on
- 34 cytoreductive surgery followed by HIPEC for peritoneal carcinomatosis,
- The committee decided that offering chemotherapy and MDT discussion of referral to a nationally commissioned specialist centre should be in the same recommendation because these interventions should happen at the same time. That is, making a referral should not
- 38 wait until chemotherapy has been given, and chemotherapy could be started before the
- 39 person is reviewed in the specilialist centre.

40 **Cost effectiveness and resource use**

- A systematic review of the economic literature was conducted but no relevant studies were
 identified which were applicable to this review question.
- 43 The recommendation to offer SACT is not anticipated to have a significant resource impact
- 44 as it is already standard practice to offer SACT to patients who are considered fit enough.
- 45 The recommendation to offer referral to specialist centres has the potential to increase the
- 46 number of referrals to specialist centres but this does not necessarily mean that more
- 47 procedures will take place because a significant proportion of patients with colorectal

- 1 peritoneal metastases are not suitable for CRS with HIPEC. Therefore it was considered
- 2 unlikely that the recommendation would have a significant resource impact. Currently in the
- 3 UK there are only 3 nationally commissioned specialist CRS and HIPEC centres. If the
- 4 demand exceeds the capacity of these centres, there may be a need to expand the current
- 5 centres or develop new centres in the future.
- 6 In cost-effectiveness terms, the use of CRS and HIPEC would increase treatment costs but
- 7 this may be offset, at least partially, by downstream cost savings associated with better
- 8 disease control. Also if potential benefits in survival were realised then the interventions
- 9 could be cost-effective in cost per QALY terms.

10 Other factors the committee took into account

- 11 The committee acknowledged the ongoing CAIRO 6 trial, which is assessing perioperative
- systemic therapy and cytoreductive surgery with HIPEC compared to upfront cytoreductive
 surgery with HIPEC alone for resectable colorectal peritoneal metastases. The results from
 this trial may provide evidence regarding optimal treatment strategies.
- 15 The committee recognised that there may be barriers to accessing specialist centres for some people who live far away from these centres due to the distance and difficulty or cost of 16 transport. The option of receiving treatment in a centre far away from home and family could 17 18 impact the decision that a patient makes about their care. There are currently 3 nationally commissioned specialist centres offering CRS with HIPEC in the country, one in 19 20 Basingstoke, one in Birmingham and one in Manchester. Even if a referral to a nationally 21 commissioned specialist centre is done, the patient would only need to travel to the specialist 22 centre once the team in the specialist centre has reviewed the patient's records and deemed CRS with HIPEC is appropriate for them. Barriers to care in the specialist centres for those 23 living far away from these centres could be alleviated by ensuring transport is available to 24 those who require assistance and suitable hostel type accommodation for relatives and 25 26 carers is made available at major referral sites when daily visiting is not realistic because of 27 the distance.

28 References

29 Mehta 2016

Mehta S, Gelli M and Agarwal D (2016) Complications of cytoreductive surgery and HIPEC in
 the treatment of peritoneal metastases. Indian Journal of Surgical Oncology 7(2): 225-229

32 Prada-Villaverde 2014

- 33 Prada-Villaverde A, Esquivel J, Lowy A, et al. (2014) The American Society of Peritoneal
- 34 Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539
- patients with colon cancer undergoing a complete cytoreductive surgery. Journal of Surgical
 Oncology 110(7): 779-785

37 **PRODIGE 7 [Quenet 2018]**

- Quenet F, Dominique E, Lise R, et al. (2018) A UNICANCER phase III trial of hyperthermic
 intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC):
- 40 PRODIGE 7. Journal of Clinical Oncology 36: LBA3503

41 van Oudheusden 2015

- 42 van Oudheusden T, Razenberg L, van Gestel Y, et al. (2015) Systemic treatment of patients
- 43 with metachronous peritoneal carcinomatosis of colorectal origin. Scientific Reports 21(5):
- 44 18632

1 Verwaal 2003

2 Verwaal V, Van Ruth S and De Bree E (2003) Randomized trial of cytoreduction and

- hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative
 surgery in patients with peritoneal carcinomatosis of colorectal cancer. Journal of Clinical
- 5 Oncology 21(20): 3737-3743
- 6 Verwaal V, Bruin S, Boot H, et al. (2008) 8-year follow-up of randomized trial: cytoreduction
- 7 and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients
- 8 with peritoneal carcinomatosis of colorectal cancer. Annals of Surgical Oncology 15(9): 2426-
- 9 32

Appendices

2 Appendix A – Review protocol

- 3 Review protocol for review question: What is the optimal combination and
- 4 sequence of local and systemic treatments in patients presenting with
- 5 metastatic colorectal cancer isolated in the peritoneum?

Table 3: Review protocol for the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic

colorectal cancer i	solated in the peritoneum
Field (based on <u>PRISMA-P)</u>	Content
Review question in guideline	What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?
Type of review question	Intervention
Objective of the review	To determine the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum.
Eligibility criteria – population/disease/condition/is sue/domain	Adults with colorectal cancer with metastases isolated in the peritoneum
	Subgroups (analysed separately):
	 Symptomatic or asymptomatic primary colorectal tumour
	 Synchronous or metachronous metastases
Eligibility criteria –	Cytoreductive surgery (CRS)
intervention(s)/exposure(s)/pro gnostic factor(s)	 CRS with hyperthermic intraperitoneal chemotherapy (HIPEC)
	Systemic anti-cancer therapy (SACT) alone
Eligibility criteria – comparator(s)/control or reference (gold) standard	Individual interventions or combinations of interventions compared to each other
,	Best supportive care Critical:
Outcomes and prioritisation	
	Progression-free survival (MID: statistical significance)Overall survival (MID: statistical significance)
	 Overall quality of life measured using validated scales (MID: published MIDs from literature, see below)
	Important:
	 Treatment-related mortality (MID: statistical significance)
	 Any grade 3 or 4 complications (MID: statistical significance)
	• Length of hospital stay (MID: statistical significance)
	Quality of life MIDs from the literature:

- Quality of life MIDs from the literature:
- EORTC QLQ-C30: 5 points

	 EORTC QLQ-CR29: 5 points EORTC QLQ-CR38: 5 points EQ-5D: 0.09 using FACT-G quintiles FACT-C: 5 points FACT-G: 5 points SF-12: > 3.77 for the mental component summary and > 3.29 for the physical component summary SF-36: > 7.1 for the physical functioning scale, > 4.9 for the bodily pain scale, and > 7.2 for the physical component summary
Eligibility criteria – study design	 Systematic reviews of RCTs RCTs Comparative observational studies will only be considered if eligible RCTs are not available
Other inclusion exclusion criteria	 Inclusion: English-language All settings will be considered that consider medications and treatments available in the UK Studies published post 1995 Studies conducted post 1995 will be considered for this review question because the guideline committee considered that some of the treatments were not commercially available before then.
Proposed sensitivity/sub-group analysis, or meta-regression	Observational studies should include multivariate analysis controlling for the following confounding factors: • Age • Synchronous or metachronous • Peritoneal cancer index
Selection process – duplicate screening/selection/analysis	Sifting, data extraction, appraisal of methodological quality and GRADE assessment will be performed by the systematic reviewer. Resolution of any disputes will be with the senior systematic reviewer and the Topic Advisor. Quality control will be performed by the senior systematic reviewer. Dual sifting will be undertaken for this question for a random 10% sample of the titles and abstracts identified by the search.
Data management (software)	Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). 'GRADEpro' will be used to assess the quality of evidence for each outcome. NGA STAR software will be used for study sifting, data extraction, recording quality assessment using checklists and generating bibliographies/citations.
Information sources – databases and dates	 Potential sources to be searched: Medline, Medline In- Process, CCTR, CDSR, DARE, HTA, Embase Limits (e.g. date, study design): Apply standard animal/non-English language exclusion

	 Limit to RCTs and systematic reviews in first instance, but download all results Dates: from 1995
Identify if an update	Not an update
Author contacts	https://www.nice.org.uk/guidance/indevelopment/gid- ng10060 Developer: NGA
Highlight if amendment to previous protocol	For details please see section 4.5 of <u>Developing NICE</u> guidelines: the manual
Search strategy – for one database	For details please see appendix B.
Data collection process – forms/duplicate	A standardised evidence table format will be used, and published as appendix D (clinical evidence tables) or H (economic evidence tables).
Data items – define all variables to be collected	For details please see evidence tables in appendix D (clinical evidence tables) or H (economic evidence tables).
Methods for assessing bias at outcome/study level	Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of <u>Developing NICE guidelines: the manual</u>
	 Appraisal of methodological quality: The methodological quality of each study will be assessed using an appropriate checklist: ROBIS for systematic reviews Cochrane risk of bias tool for RCTs ROBINS-I for non-randomised studies The quality of the evidence for an outcome (i.e. across studies) will be assessed using GRADE.
	The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group http://www.gradeworkinggroup.org/
Criteria for quantitative synthesis (where suitable)	For details please see section 6.4 of <u>Developing NICE</u> guidelines: the manual
Methods for analysis – combining studies and exploring (in)consistency	Synthesis of data: Pairwise meta-analysis of randomised trials will be conducted where appropriate. When meta-analysing continuous data, final and change scores will be pooled if baselines are comparable. If any studies report both, the method used in the majority of studies will be analysed.
	Minimally important differences : The guideline committee identified statistically significant differences as appropriate indicators for clinical significance for all outcomes except quality of life for which published MIDs from literature will be used (see outcomes section for more information).

Meta-bias assessment – publication bias, selective reporting bias	For details please see section 6.2 of <u>Developing NICE</u> <u>guidelines: the manual</u> . If sufficient relevant RCT evidence is available,
	publication bias will be explored using RevMan 5 software to examine funnel plots.
Assessment of confidence in cumulative evidence	For details please see sections 6.4 and 9.1 of <u>Developing</u> <u>NICE guidelines: the manual</u>
Rationale/context – Current management	For details please see the introduction to the evidence review.
Describe contributions of authors and guarantor	A multidisciplinary committee developed the guideline. The committee was convened by The National Guideline Alliance and chaired by Peter Hoskin in line with section 3 of <u>Developing NICE guidelines: the manual</u> Staff from The National Guideline Alliance undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the guideline in collaboration with the committee. For details please see Supplement 1.
Sources of funding/support	The NGA is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists.
Name of sponsor	The NGA is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists
Roles of sponsor	NICE funds the NGA to develop guidelines for those working in the NHS, public health, and social care in England
PROSPERO registration number	Not registered

CCTR: Cochrane Central Register of Controlled Trials; CDSR: Cochrane Database of Systematic Reviews; DARE: Database of Abstracts of Reviews of Effects; EQ-5D: EuroQol five dimensions questionnaire; EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items; EORTC QLQ-CR29: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire colorectal cancer module (29 items); EORTC QLQ-CR38: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire colorectal cancer module (38 items); FACT-C: Functional Assessment of Cancer Therapy questionnaire (colorectal cancer); FACT-G: Functional Assessment of Cancer Therapy questionnaire (general); GRADE: Grading of Recommendations Assessment, Development and Evaluation; HTA: Health Technology Assessment; MID: minimal important difference; NGA: National Guideline Alliance; NHS: National Health Service; NICE: National Institute for Health and Care Excellence; PRISMA-P: Preferred Reporting Items for Systematic reviews and Meta-Analysis Protocols; PROSPERO: International prospective register of systematic reviews; RCT: randomised controlled trial; ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions; ROBIS: a tool for assessing risk of bias in systematic reviews; SF-12: 12-Item Short Form Survey; SF-36: 36-Item Short Form Survey

12345678901123451112345

Colorectal cancer (update): evidence review for treatment for metastatic colorectal cancer in the peritoneum FINAL (January 2020)

1 Appendix B – Literature search strategies

2 Literature search strategies for review question: What is the optimal combination

- 3 and sequence of local and systemic treatments in patients presenting with
- 4 metastatic colorectal cancer isolated in the peritoneum?

5 Databases: Embase/Medline

6 Last searched on: 21/05/2018

1 (exp colorectal cancer/ or exp colon tumour/ or exp rectum tumour/) use emez 2 exp colorectal neoplasms/ use ppez 1 ((colorect' or color eci o colonic or rectal or rectum) adj3 (adenocarcinoma' or cancer' or carcinoma' or malignan' or neoplas' or oncolog' or tumo?(*)).tw. 4 or(1-3 5 Peritoneum metastasis/ use emez 6 peritoneal neoplasms/ use ppez 7 ((peritoneum or peritoneal) adj3 (disseminat' or metasta' or migrat')).tw. 8 (colorect' or color eci or colonic or rectal or rectum) adj3 (peritoneum metasta' or peritoneal metasta' or peritoneal carcinom')).tw. 9 or/5-7 10 4 and 9 11 10 or 8 12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy! 14 (cytoreductive surgers/ use emez 15 or/12-14 16 exp antineoplastic agent/ use ppez 17 exp antineoplastic agent/ use emez 20 cancer therapy/ use emez 21 cancer combination chernebrapy use emez 22 cancer combination chernebrapay use emez <th>#</th> <th>Search</th>	#	Search
3 ((colorect* or color ect* or colon or colonic or rectal or rectum) adj3 (adenocarcinoma* or cancer* or carcinoma* or malignan* or neoplas* or oncolog* or tumo?r*)).tw. 4 or(1-3) 5 Peritoneum metastasis/ use emez 6 peritoneum or peritoneu) adj3 (disseminat* or metasta* or migrat*)).tw. 8 ((colorect* or color ect* or colon or colonic or rectal or rectum) adj3 (peritoneum metasta* or peritoneal metasta* or peritoneal carcinom*)).tw. 9 or(5-7 10 4 and 9 11 10 or 8 12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agent/ use emez 18 exp Antineoplastic agent/ use emez 20 cancer thrapy/ use emez 21 exp chemotherapy/ use emez 22 cancer vaccine/ use emez 23 cancer vaccine/ use emez 24 cancer vaccine/ use emez 25 cancer vac	1	(exp colorectal cancer/ or exp colon tumour/ or exp rectum tumour/) use emez
mailgnant* or neoplas* or oncolog* or tumo?r*)).tw. 4 or/1-3 5 Pertioneum metastasis/ use emez 6 pertioneum metastasis/ use ppez 7 ((pertioneum or peritoneal) adj) (disseminat* or metasta* or migrat*)).tw. 8 ((cortor or cortoneal) adj) (disseminat* or metasta* or migrat*)).tw. 9 or/5-7 10 4 and 9 11 10 or 8 12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures/ use ppez or laparotomy/ 14 (cytoreduc* or cyto-reduc* or CRS or debuik* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent// use emez 17 exp antineoplastic agent// use emez 18 exp Antineoplastic agent// use emez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chmotherapy/ use emez 22 cancer therapy/ use emez 23 cancer twacrine// use emez 24 cancer twacrine// use emez	2	exp colorectal neoplasms/ use ppez
5 Peritoneum metastasis/ use emez 6 peritoneum or peritoneal) adj3 (disseminat* or metasta* or migrat*)).tw. 7 ((peritoneum or peritoneal) adj3 (disseminat* or metasta* or migrat*)).tw. 9 or/5-7 11 10 or 8 0 or/for-fouctive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 exp antineoplastic agent/ use emez 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agent/ use ppez 18 exp antineoplastic agent/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer immunotherapy/ use emez 23 cancer vaccine/ use ppez 24 cancer vaccine/ use ppez 25 cancer vaccine/ use ppez 26 exp antihocolastin chemotherapy/ use emez 27 ((anti canc* or anticanc* or anticancrogen* or anti actionegin* or antimeoplas* or antitumo?* or anticanc** or anticancrogen* or anti antime** or therap*).tw. 27 ((anti canc* or anticanc**) adj (agent** or duod* or protocol* or engine** or tantime** or therap*).t	3	
6 peritoneal neoplasms/ use ppez 7 ((peritoneum or peritoneal) adj3 (disseminat* or metasta* or migrat*)).tw. 8 ((colorect* or color ect* or color or coloni or rectal or rectum) adj3 (peritoneum metasta* or peritoneal metasta* or peritoneal carcinom*)).tw. 9 or/5-7 10 4 and 9 11 10 or 8 12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreduc* or cyto-reduc* or CRS or debuik* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agent/ use emez 18 exp Antineoplastic Protocols/ use ppez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer vaccine/ use emez 23 Cancer Vaccine/ use emez 24 cancer vaccine/ use emez 25 cancer vaccine/ use emez 26 exp antibodies, monoclonal / use ppez or monoclonal antibody/ use emez 27	4	or/1-3
7 ((peritoneum or peritoneal) adj3 (disseminat* or metasta* or migrat*)).tw. 8 ((colorect* or colon or colonic or rectal or rectum) adj3 (peritoneum metasta* or peritoneal metasta* or peritoneal acrinom*)).tw. 9 or/5-7 10 4 and 9 11 10 or 8 2 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agent/ use ppez 18 exp Antineoplastic agent/ use ppez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer vaccine/ use emez 23 Cancer Vaccines/ use emez 24 cancer vaccine/ use emez 25 cancer vaccine/ use emez 26 exp antibodies, monoclonal (use ppez or monoclonal antibody/ use emez 27 ((anti canc* or anticancerogen* or anticancerogen* or resent* or biological therap*).tw. <td>5</td> <td>Peritoneum metastasis/ use emez</td>	5	Peritoneum metastasis/ use emez
8 ((colorect* or colo rect* or colon ic or rectal or rectum) adj3 (peritoneum metasta* or peritoneal metasta* or peritoneal carcinom*)).tw. 9 or/5-7 10 4 and 9 11 10 or 8 12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreduct* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic Protocols/ use ppez 18 exp Antineoplastic Protocols/ use ppez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer vaccine/ use ppez 23 Cancer Vaccine/ use emez 24 cancer vaccine/ use emez 25 cancer immunotherapy/ use emez 26 exp antiloodies, monoclonal/ use ppez or monoclonal antibody/ use emez 26 exp antiloodies, monoclonal/ use ppez or monoclonal antibody/ use emez 26 exp antiloodies, monoclonal/ use ppez or monoclonal antibody/ use emez </td <td>6</td> <td>peritoneal neoplasms/ use ppez</td>	6	peritoneal neoplasms/ use ppez
 pertoneal carcinom*)).tw. 9 or/5-7 4 and 9 11 10 or 8 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ (cytoreductive cyto-reduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. or/12-14 exp antineoplastic agent/ use emez exp antineoplastic agent/ use ppez exp antineoplastic agent/ use ppez exp antineoplastic agent/ use emez cancer therapy/ use emez cancer therapy/ use emez cancer therapy/ use emez cancer vaccine/ use ppez cancer vaccine/ use ppez cancer vaccine/ use emez dagant* or drug* or	7	((peritoneum or peritoneal) adj3 (disseminat* or metasta* or migrat*)).tw.
10 4 and 9 11 10 or 8 12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreductive surgery/ use emez or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agent/ use ppez 18 exp Antineoplastic agent/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer therapy/ use emez 23 Cancer vaccine/ use emez 24 cancer vaccine/ use emez 25 cancer immunotherapy/ use emez 26 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez 27 ((anti canc* or anticance* or regimen* or treatment* or therap*)).tw. 28 GACT or chemosaturat* or chemotherap* or inmunotherap* or biological agent* or biological therap*)).tw. 29 or/16-28 31 11 and 30 32 Letter/, o	8	
11 10 or 8 12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic restorely use emez 18 exp Antineoplastic Protocols/ use ppez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer combination chemotherapy/ use emez 23 Cancer Vaccine/ use ppez 24 cancer vaccine/ use emez 25 cancer immunotherapy/ use emez 26 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez 27 ((anti canc* or anticancerogen* or anticanciengen* or antineoplas* or antineoplas* or antitumo?r* or antitumo?r* or anticancerogen* or anticencerogen* or regimen* or treatment* or therap*)).tw. 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use ppez 33	9	or/5-7
12 cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez 13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agents/ use emez 18 exp Antineoplastic Protocols/ use ppez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer vaccine/ use emez 23 Cancer Vaccines/ use ppez 24 cancer vaccine/ use emez 25 cancer vaccine/ use emez 26 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez 27 ((anti canc* or anticancerogen* or anticarcinogen* or anti neoplas* or anti neoplas* or anti tumo?r* or antitumo?r* or cytotxic*) adj (agent* or drug* or protoco* or regimen* or treatment* or therap*).tw. 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use emez 33 letter, pt. or letter/ use emez	10	4 and 9
13 surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/ 14 (cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agents/ use ppez 18 exp Antineoplastic agents/ use ppez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer combination chemotherapy/ use emez 23 Cancer Vaccine/ use emez 24 cancer vaccine/ use emez 25 cancer or anticancerogen* or anticarcinogen* or anti neoplas* or anti numo?r* or antitumo?r* or antitumo?r* or anticancerogen* or anticarcinogen* or anti neoplas* or anti neoplas* or anti numo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*).tw. 29 or/16-28 31 11 and 30 32 Letter/ use ppez 33 letter, pt. or letter/ use emez 34 note.pt. 35 editorial.pt. 36 Editorial.pt. 37 News/ use ppez 38 <t< td=""><td>11</td><td>10 or 8</td></t<>	11	10 or 8
14 (cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw. 15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agent/ use ppez 18 exp Antineoplastic agent/ use emez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer combination chemotherapy/ use emez 23 Cancer vaccine/ use ppez 24 cancer vaccine/ use emez 25 cancer or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or anti neoplas* or anti tumo?t* or antitumo?t* or antitumo?t* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or biological therap*).tw. 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use ppez 33 letter, pt. or letter/ use emez 34 note, pt. 35 editorial, pt. 36 Editorial use ppez 37 News/ use ppez 38 etter/ use ppez 39 Anecdotes as Topic/ use ppez <	12	cytoreductive surgery/ use emez or cytoreduction Surgical Procedures/ use ppez
15 or/12-14 16 exp antineoplastic agent/ use emez 17 exp antineoplastic agents/ use ppez 18 exp Antineoplastic Protocols/ use ppez 19 multimodality cancer therapy/ use emez 20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer combination chemotherapy/ use emez 23 Cancer Vaccines/ use ppez 24 cancer vaccine/ use emez 25 cancer vaccine/ use emez 26 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez 27 ((anti canc' or anticancer or anticancerogen' or anticarcinogen' or antineoplas' or antineoplas' or anti tumo?r* or antitumo?r* or antitumo?r* or anticancerogen* or protocol* or regimen* or treatment* or therap*)).tw. 28 (SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw. 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use ppez 33 letter, pl. or letter/ use emez 34 note.pt. 35 editorial pt. 36 Editorial pt. 37 News/ use ppez	13	surgery/ use emez or surgical procedures, operative/ use ppez or laparotomy/
Interplastic agent/ use emez17exp antineoplastic agents/ use ppez18exp Antineoplastic Protocols/ use ppez19multimodality cancer therapy/ use emez20cancer therapy/ use emez21exp chemotherapy/ use emez22cancer therapy/ use emez23Cancer Vaccine/ use ppez24cancer vaccine/ use emez25cancer vaccine/ use emez26exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez27((anti canc' or anticance' or anticancerogen' or anticarcinogen' or ratin neoplast' or antineoplast or anti umo?r* or antitumo?r* or cantitumo?r* or cantitumo?r* or cantitumo?r* or cytotoxic') adj3 (agent' or drug' or protocol' or regimen' or treatment' or therap*).tw.28(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.29or/16-283015 or 293111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial.pt.37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	14	(cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*).tw.
17exp antineoplastic agents/ use ppez18exp Antineoplastic Protocols/ use ppez19multimodality cancer therapy/ use emez20cancer therapy/ use emez21exp chemotherapy/ use emez22cancer combination chemotherapy/ use emez23Cancer Vaccines/ use ppez24cancer vaccine/ use emez25cancer immunotherapy/ use emez26exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez27((anti canc* or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*).tw.28(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.29or/16-283015 or 293111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial.pt.37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	15	or/12-14
18exp Antineoplastic Protocols/ use ppez19multimodality cancer therapy/ use emez20cancer therapy/ use emez21exp chemotherapy/ use emez22cancer combination chemotherapy/ use emez23Cancer Vaccines/ use ppez24cancer vaccine/ use emez25cancer immunotherapy/ use emez26exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez27((anti cance' or anticancerogen* or anticarcinogen* or anti neoplas* or anti tumo?r* or antinumo?r* or antitumo?r* or antitumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*).tw.28(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.29or/16-283015 or 293111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial.pt.37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	16	exp antineoplastic agent/ use emez
19multimodality cancer therapy/ use emez20cancer therapy/ use emez21exp chemotherapy/ use emez22cancer combination chemotherapy/ use emez23Cancer Vaccines/ use ppez24cancer vaccine/ use emez25cancer vaccine/ use emez26exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez27((anti canc* or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw.28(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.29or/16-283015 or 293111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial.pt.37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	17	exp antineoplastic agents/ use ppez
20 cancer therapy/ use emez 21 exp chemotherapy/ use emez 22 cancer combination chemotherapy/ use emez 23 Cancer Vaccines/ use ppez 24 cancer vaccine/ use emez 25 cancer immunotherapy/ use emez 26 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez 26 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez 27 ((anti canc* or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or antineoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw. 28 (SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw. 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use ppez 33 letter.pt. or letter/ use emez 34 note.pt. 35 editorial.pt. 36 Editorial/use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez	18	exp Antineoplastic Protocols/ use ppez
21exp chemotherapy/ use emez22cancer combination chemotherapy/ use emez23Cancer Vaccines/ use ppez24cancer vaccine/ use emez25cancer immunotherapy/ use emez26exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez27((anti canc* or anticancerogen* or anticarcinogen* or anti neoplas* or anti neoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw.28(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.29or/16-283015 or 293111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial.pt.37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	19	multimodality cancer therapy/ use emez
22 cancer combination chemotherapy/ use emez 23 Cancer Vaccines/ use ppez 24 cancer vaccine/ use emez 25 cancer immunotherapy/ use emez 26 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez 27 ((anti canc* or anticancer ogen* or anticarcinogen* or anti neoplas* or anti neoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw. 28 (SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*)).tw. 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use ppez 33 letter.pt. or letter/ use emez 34 note.pt. 35 editorial.pt. 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez	20	cancer therapy/ use emez
 Cancer Vaccines/ use ppez cancer vaccine/ use emez cancer immunotherapy/ use emez exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez ((anti canc* or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or anti neoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw. (SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw. or/16-28 15 or 29 11 and 30 Letter/ use ppez letter.pt. or letter/ use emez editorial.pt. Editorial.pt. Editorial/ use ppez News/ use ppez a exp Historical Article/ use ppez Anecdotes as Topic/ use ppez 	21	exp chemotherapy/ use emez
24cancer vaccine/ use emez25cancer immunotherapy/ use emez26exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez27((anti canc* or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or antineoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw.28(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.29or/16-283015 or 293111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial/ use ppez37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	22	cancer combination chemotherapy/ use emez
 cancer immunotherapy/ use emez exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez ((anti canc* or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or antineoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw. (SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw. or/16-28 15 or 29 11 and 30 Letter/ use ppez letter.pt. or letter/ use emez note.pt. editorial.pt. Editorial/ use ppez News/ use ppez exp Historical Article/ use ppez Anecdotes as Topic/ use ppez Anecdotes as Topic/ use ppez 	23	Cancer Vaccines/ use ppez
 exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez ((anti canc* or anticance* or anticancerogen* or anticarcinogen* or anti neoplas* or antineoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw. (SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw. or/16-28 15 or 29 11 and 30 Letter/ use ppez letter.pt. or letter/ use emez note.pt. editorial.pt. Editorial/ use ppez News/ use ppez exp Historical Article/ use ppez Anecdotes as Topic/ use ppez 	24	cancer vaccine/ use emez
 27 ((anti canc* or anticanc* or anticancerogen* or anticarcinogen* or anti neoplas* or antineoplas* or anti tumo?r* or antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw. 28 (SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw. 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use ppez 33 letter.pt. or letter/ use emez 34 note.pt. 35 editorial.pt. 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	25	cancer immunotherapy/ use emez
antitumo?r* or cytotoxic*) adj3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)).tw.28(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.29or/16-283015 or 293111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial/ use ppez37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	26	exp antibodies, monoclonal/ use ppez or monoclonal antibody/ use emez
 29 or/16-28 30 15 or 29 31 11 and 30 32 Letter/ use ppez 33 letter.pt. or letter/ use emez 34 note.pt. 35 editorial.pt. 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	27	
 15 or 29 11 and 30 Letter/ use ppez letter.pt. or letter/ use emez note.pt. editorial.pt. Editorial/ use ppez Kews/ use ppez exp Historical Article/ use ppez Anecdotes as Topic/ use ppez 	28	(SACT or chemosaturat* or chemotherap* or immunotherap* or biological agent* or biological therap*).tw.
3111 and 3032Letter/ use ppez33letter.pt. or letter/ use emez34note.pt.35editorial.pt.36Editorial/ use ppez37News/ use ppez38exp Historical Article/ use ppez39Anecdotes as Topic/ use ppez	29	or/16-28
 32 Letter/ use ppez 33 letter.pt. or letter/ use emez 34 note.pt. 35 editorial.pt. 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	30	15 or 29
 33 letter.pt. or letter/ use emez 34 note.pt. 35 editorial.pt. 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	31	11 and 30
 34 note.pt. 35 editorial.pt. 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	32	Letter/ use ppez
 35 editorial.pt. 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	33	letter.pt. or letter/ use emez
 36 Editorial/ use ppez 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	34	note.pt.
 37 News/ use ppez 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	35	editorial.pt.
 38 exp Historical Article/ use ppez 39 Anecdotes as Topic/ use ppez 	36	Editorial/ use ppez
39 Anecdotes as Topic/ use ppez	37	News/ use ppez
	38	exp Historical Article/ use ppez
40 Comment/ use ppez	39	Anecdotes as Topic/ use ppez
	40	Comment/ use ppez

FINAL

Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

#	Search
41	Case Report/ use ppez
42	case report/ or case study/ use emez
43	(letter or comment*).ti.
44	or/32-43
45	randomized controlled trial/ use ppez
46	randomized controlled trial/ use emez
47	random*.ti,ab.
48	or/45-47
49	44 not 48
50	animals/ not humans/ use ppez
51	animal/ not human/ use emez
52	nonhuman/ use emez
53	exp Animals, Laboratory/ use ppez
54	exp Animal Experimentation/ use ppez
55	exp Animal Experiment/ use emez
56	exp Experimental Animal/ use emez
57	exp Models, Animal/ use ppez
58	animal model/ use emez
59	exp Rodentia/ use ppez
60	exp Rodent/ use emez
61	(rat or rats or mouse or mice).ti.
62	or/49-61
63	31 not 62
64	limit 63 to (yr="1995 - current" and english language)
65	remove duplicates from 64

1 Database: Cochrane Library

2 Last searched on: 21/05/2018

#	Search
1	MeSH descriptor: [Colorectal Neoplasms] explode all trees
2	((colorect* or colo rect* or colon or colonic or rectal or rectum) near/3 (adenocarcinoma* or cancer* or carcinoma* or malignan* or neoplas* or oncolog* or tumo?r*)):ti,ab,kw (Word variations have been searched)
3	#1 or #2
4	MeSH descriptor: [Peritoneal Neoplasms] explode all trees
5	MeSH descriptor: [Peritoneum] explode all trees
6	MeSH descriptor: [Neoplasm Metastasis] explode all trees
7	#5 and #6
8	((peritoneum or peritoneal) near/3 (disseminat* or metasta* or migrat*)):ti,ab,kw
9	((colorect* or colo rect* or colon or colonic or rectal or rectum) near/3 (peritoneum metasta* or peritoneal metasta* or peritoneal carcinom*)):ti,ab,kw
10	#4 or #7 or #8
11	#3 and #10
12	#11 or #9
13	MeSH descriptor: [Cytoreduction Surgical Procedures] this term only
14	MeSH descriptor: [Surgical Procedures, Operative] explode all trees
15	MeSH descriptor: [Laparotomy] explode all trees
16	(cytoreduc* or cyto-reduc* or CRS or debulk* or excis* or peritonectom* or operat* or resect* or surg*):ti,ab,kw
17	MeSH descriptor: [Antineoplastic Agents] explode all trees
18	MeSH descriptor: [Antineoplastic Protocols] explode all trees
19	MeSH descriptor: [Cancer Vaccines] this term only
20	MeSH descriptor: [Antibodies, Monoclonal] explode all trees
21	((anti canc* or anticanc* or anticarcinogen* or anti neoplas* or antineoplas* or cytotoxic*) near/3 (agent* or drug* or protocol* or regimen* or treatment* or therap*)):ti,ab,kw (Word variations have been searched)

FINAL


Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

#	Search
22	(SACT or chemotherap* or immunotherap* or biological agent* or biological therap*):ti,ab,kw (Word variations have been searched)
23	{or #13-#22}
24	#12 and #23 Publication Year from 1995 to 2018

1 Appendix C – Clinical evidence study selection

- 2 Clinical study selection for: What is the optimal combination and sequence of
- 3 local and systemic treatments in patients presenting with metastatic colorectal
- 4 cancer isolated in the peritoneum?

Figure 1: Study selection flow chart



1 Appendix D – Clinical evidence tables

2 Clinical evidence tables for review question: What is the optimal combination and sequence of local and systemic treatments

3 in patients presenting with metastatic colorectal cancer isolated in the peritoneum?

4 Table 4: Clinical evidence tables

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
Full citation PRODIGE	Sample size N= 265	Interventions	Details	Results	Limitations
7 F, Quenet; E,	CRS + HIPEC= 133	CRS+HIPEC+oxaliplatin vs	Randomisation: Patients are	Overall survival	Risk of bias assessed using
Dominique; R, Lise; G,	CRS alone= 132	CRS alone	stratified (1:) according to	(median follow up	Cochrane risk of bias tool
Diane; G, Laurent; P,			participating centre, residual	63.8 months), HR	Random sequence
Marc; O, Facy; A,	Characteristics "Baseline	HIPEC: "Patients undergo	tumuor status (R0/R1 vs R2 ≤ 1	(CI), p-value 1.00	generation: Unclear
Catherine; et al, A	characteristics were well	surgery and receive standard	mm), prior regimens of	(0.73-1.37), 0.995	(randomisation procedure
UNICANCER phase III	balanced"	systemic chemotherapy	systemic chemotherapy (first vs		not reported)
trial of hyperthermic		comprising leucovorin calcium	≥ second), and preoperative	Post-	Allocation concealment:
intra-peritoneal	Median age, years= 60 (30-74)	IV followed by fluorouracil IV	systemic chemotherapy for	operative mortality, n	Low risk (not concealed, bu
chemotherapy (HIPEC)		over 30 minutes. Systemic	metastatic disease (yes vs no)	CRS + HIPEC= 2/133	unlikely to affect outcome
for colorectal peritoneal	Inclusion criteria Adults aged	chemotherapy will continue for	Allocation concealment: Not	CRS alone= 2/132	assessment)
carcinomatosis (PC):	18-70 with histologically	at least 6 months (before and	reported	60-day grade 3-5	Blinding of participants and
PRODIGE 7, Journal of	confirmed colorectal cancer,	after surgery). Patients also	Blinding: Not reported	morbidity, n	personnel: Low risk (open
Clincal Oncology, 36,	peritoneal carcinoma extension	undergo CHIP comprising	Attrition: Not reported	CRS + HIPEC=	label, but unlikely to affect
LBA3503, 2018	≤ 25 (Sugarbaker Index)	oxaliplatin intraperitoneally	Statistical analysis: Not	32/133	outcome assessment)
	(determined intraoperatively),	during surgery and	reported	CRS alone= 18/132	Blinding of outcome
Ref ld 930671	planning to receive standard	hyperthermia for 30 minutes."	Follow up: 1 and 3 months after		assessment: Low risk
	systemic chemotherapy,		study therapy, every 3 months		(unblinded, unlikely to affect
Country/ies where the		Standard: "Patients undergo	for 3 years, and then every 6		outcome assessment)
study was carried out	cancer should be initiated 3	surgery and receive standard	months for 2 years		Incomplete outcome data:
France	months after surgery,	systemic chemotherapy	Outcomes: Primary - 3 year		Unclear risk (Stated that
	macroscopically complete	comprising leucovorin calcium	overall survival. Secondary- 3		264 patients were
	resection (R1) or surgical	IV followed by fluorouracil IV	year recurrence free survival;		randomised, but then
RCT	reduction of tumour to a	over 30 minutes. Systemic	morbidity from surgical		reported 265 patients in the
	residual thickness ≤ 1 mm (R2)	chemotherapy will continue for	complications		Results, so a discrepancy i
Aim of the study The	is possible, WHO performance	at least 6 months (before and			their reporting; Did not stat
aim of the study was to	status 0-1, life expectancy > 12	after surgery)."			how attrition was managed
assess the	weeks, ANC \geq 1,500/mm ³ ,				Selective reporting: High
effectiveness	platelet count ≥				risk (not all outcomes
of hyperthermic	100,000/mm ^{3,} total bilirubin ≤				reported in Protocol
intraperitoneal	1.5 times upper limit of normal (ULN), AST and ALT \leq 3 times				reported in Abstract; full tex
chemotherapy (HIPEC)	(ULN) , AST and ALT ≤ 3 limes				not yet available)

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
on postoperative outcomes after cytoreductive surgery (CRS) for the treatment of peritoneal carcinomatosis of colorectal origin. Study dates February 2008 to January 2014 Source of funding UNICANCER	ULN, alkaline phosphatase ≤ 3 times ULN, creatinine ≤ 1.25 times ULN, eligible for surgery. Exclusion criteria No prior chemohyperthermia or concurrent participation in another study of first-line therapy for this cancer, extraperitoneal metastases, including liver and lung metastasis, carcinomatosis of other origin besides colorectal, in particular appendical carcinomatosis, peripheral neuropathy > grade 3, pregnant or nursing, other cancer in the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix, inability to submit to follow-up medical testing for geographical, social, or psychological reasons.				Other bias: Full text of study not yet available.
Full citation van Oudheusden, T. R., Razenberg, L. G., van Gestel, Y. R., Creemers, G. J., Lemmens, V. E., de Hingh, I. H., Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin, Scientific Reports, 5, 18632, 2015 Ref Id 859167 Country/ies where the	Sample size N= 186 n systemic treatment= 92 n no systemic treatment= 94 Characteristics Systemic treatment, n= 92 Male, n= 49 Age, years, < 70=62 Age, years, < 70=62 Age, years, > 70=30 Tumour differentiation, n Good=5 Moderate=52 Poor/undifferentiated=20 Unknown=15 Primary location, n Left=41 Right=37 Rectum/rectosigmoid=9	Interventions Systemic treatment versus no systemic treatment Systemic treatment: Received chemotherapy in a palliative setting. 36/92 patients also received treatment including Bevacizumab No systemic treatment: No treatment	Details Data collection: Data was extracted from the Eindhoven Cancer Registry that collects data of patients with newly diagnosed cancer in the Southern part of the Netherlands. Data on metachronous metastases were additionally collected between 2010 and 2011 for all patients who were diagnosed with M0 colorectal cancer between 2003 and 2008 in the Dutch Eindhoven Cancer Registry. Outcomes: Overall survival Follow-up: Time from diagnosis of PC to death or end of follow	Results Overall survival, HR (Cl) Chemotherapy only= 0.51 (0.35-0.73) Chemotherapy + bevacizumab= 0.35 (0.22-0.56) No treatment= reference p-value= 0.10 Median overall survival, months (Cl) Chemotherapy only= 13.0 (9.5-16.0) Chemotherapy + bevacizumab= 20.3 (13.7-29.3)	Limitations Risk of bias assessed using the ROBINS-I checklist for non-randomised studies of interventions Pre-intervention Bias due to confounding: High risk of bias (differences in characteristics between groups at baseline) Bias in selection of participants into the study: Low risk of bias Bias in classification of interventions: Low risk of bias Post-intervention Bias due to deviations from

FINAL Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
Netherlands Study type Retrospective cohort study Aim of the study The aim of the study was to assess the use and effect of palliative systemic treating in patients with metachronous peritoneal carcinomatosis of colorectal origin. Study dates 2003- 2008 and 2010-2011 Source of funding This study was funded by the Netherlands Organisation for Health Research and development (ZonMw), project numbers 152002012 and 152001022 and was supported by an unrestricted grant from Roche Pharmaceuticals.	Overlapping/NOS=5 Histology, n Mucinous=26 Adenocarcinoma=64 Signet ring cell=2 Unknown=0 T-stage, n T1/2=3 T3=68 T4=21 N-stage, n N0=36 N1=35 N2=21 NX=0 M-status, n PC only=32 PC+distant=60 No systemic treatment, n= 94 Male, n=40 Age, years, < 70=29 Age, years, < 70=29 Age, years, < 70=65 Tumour differentiation, n Good=4 Moderate=53 Poor/undifferentiated=23 Unknown=14 Primary location, n Left=32 Right=46 Rectum/rectosigmoid=15 Overalpping/NOS=1 Histology, n Mucinous=21 Adenocarcinoma=70 Signet ring cell=2 Unknown=1 T-stage, n T1/2=6 T3=65 T4=23		up period (January 2014) Statistical analysis: "Univariable and multivariable logistic regression analysis were used to identify predictors of treatment with Bevacizumab. Only variables with $p < 0.10$ in the univariate analysis were included in the multivariable analysis. The predictors were depicted as odds ratios with their 95% confidence intervals. The effect of systemic treatment on mortality was investigated using multivariable cox regression analyses and depicted as hazard ratios. Survival was determined using the Kaplan-Meier method and compared using a Log-rank test. All tests were two sided and p-value < 0.05 was considered to be significant."	No treatment= 3.4	intended interventions: Unclear risk of bias (The group of patients without comorbidities received Bevacizumab more often (42% versus. 30%, P = 0.07) Bias due to missing data: Low risk of bias Bias in measurement of outcomes: Low risk of bias Bias in selection of the reported result: Low risk of bias Other information "Moreover, a significant proportion of patients had also other distant metastases. It is therefore uncertain to what extent increased survival can be attributed to the treatment o the peritoneal deposits in these patients, especially so since the effectiveness of targeted therapies in non- peritoneal metastases is supported by stronger evidence"

FINAL

Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	N-stage, n N0=29 N1=31 N2=32 NX=2 M-status, n PC only=47 PC + distant=47 Inclusion criteria Patients with metachronous PC of colorectal origin who received systemic treatment in a palliative setting Exclusion criteria Patients that underwent curative surgery for PC (CRS + HIPEC) or were receiving targeted therapy prior to PC diagnosis and those who did not undergo a curative primery turnour recention				
Full citation Verwaal, V. J., Van Ruth, S., De Bree, E., Van Slooten, G. W., Van Tinteren, H., Boot, H., Zoetmulder, F. A. N., Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer, Journal of Clinical Oncology, 21, 3737- 3743, 2003 Ref Id 859186	1=9	Interventions CRS + HIPEC + SCT versus standard (surgery + SCT) CRS+HIPEC+SCT: CRS= "The objective of cytoreduction was to leave no macroscopic tumour behind, or at least to have limited residual tumour (2.5 mm in thickness). To achieve this, the stripping of the parietal peritoneum was carried out as described by Sugarbaker et al. Infiltrated viscera were resected if this was compatible with retaining function. Most often this concerned the rectum, parts of small bowel and colon, the gall bladder, parts of the stomach, and the spleen. The greater omentum was routinely	Details Randomisation: performed centrally through a computer Allocation concealment: Not reported Blinding: Not reported Attrition: one patient lost to follow up, intention to treat analysis used Statistical analysis: "The survival was estimated by the Kaplan-Meier method and tested with the log-rank test following the intention-to-treat principle. The analysis was planned at a median follow-up of 2 years to have 80% power to detect a 20% absolute difference in survival. To detect this difference, with P < .05 (two-tailed test), at least 100	Results Overall survival at 2 years, HR (Cl), p- value CRS+HIPEC+SCT= 0.55 (0.32-0.95), 0.032 Standard= reference Overall survival, median follow up 21.6 months (event is overall survival) CRS+HIPEC+SCT= 30/54 (55.6%) Standard=20/51 (39.2%) p-value not reported Treatment-related mortality (30-day	Limitations Risk of bias assessed using Cochrane risk of bias tool Random sequence generation: Low risk of bias (computer generated) Allocation concealment: Unclear risk of bias (not reported) Blinding of participants and personnel: Low risk of bias (blinding of participants and personnel not possible, and outcome is not likely to be influenced by lack of blinding) Blinding of outcome assessment: Low risk of bias (blinding of outcome assessment not reported however outcome is not

FINAL Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	Rectum=6	removed. Reconstruction of	patients had to be entered."	mortality), n (for the	likely to have been
Country/ies where the	Differentiation grade, n	gastrointestinal continuity was	Follow up: 2 years	48 patients who	influenced by lack of
study was carried out	Good=5	postponed until after the	Outcomes: Survival (time from	underwent CRS	blinding)
Netherlands	Moderate=33	lavage, to prevent entrapment	randomisation to death from	followed by HIPEC in	Incomplete outcome
	Poor=15	of tumour cells in suture lines."	any cause)	the experimental arm)	data: Unclear risk of bias
Study type Single-		HIPEC - "To increase the		CRS+HIPEC+SCT=	(stated that one patient was
centre RCT	Standard, n= 51	volume of the abdominal cavity		4/48	lost to follow up but
	Male, n=24	and to prevent spillage of		Standard= 0/51	intention-to-treat analysis)
Aim of the study The	Age, years, median (IQR)= 55	lavage fluid, the skin of the			Selective reporting: Low risl
aim of the study was to		laparotomy wound was pulled		Median hospital stay,	of bias (all outcomes stated
assess the	Performance status, n	up against a retractor. A plastic		days, median (IQR)	in Methods were reported in
effectiveness of CRS	Not recorded=19	sheet covered the laparotomy		(for the 49 patients	Results)
with HIPEC compared	0=23	opening to reduce heat loss		who underwent	Other bias: None
to standard treatment	1=7	and to avoid drug spilling. A		surgery in the	
for patients with	2=2	central aperture was made to		experimental arm)	Other information
peritoneal	Presentation at randomisation,	allow manipulation to achieve		CRS+HIPEC+SCT=	7/51 patients in the
carcinomatosis of	n	optimal drug and heat		29 (6-166)	standard arm never started
primary colorectal	Primary=28	distribution. The perfusion		Standard= not	SCT due to withdrawing
cancer.	Recurrent=23	circuit consisted of a centrally		reported	consent or severe disease
	Primary tumour, n	placed inflow catheter, outflow			progression. 12/38 patients
Study dates February	Appendix=11	catheters, placement in the			who started SCT in the
1998 to August 2001	Colon=34	pelvis below left and right			standard arm stopped
	Rectum=6	diaphragm, a roller pump, and			because of disease
	Differentiation grade, n	a heat exchanger. Temperature			progression, toxicity or were
reported	Good=3	probes were attached to inflow			still on treatment.
	Moderate=27	and outflow catheters.			5/54 patients in the
	Poor=18	Perfusion was started with a			CRT+HIPEC+SCT arm did
		minimum of 3 L of isotonic			undergo CRT followed by
	Inclusion criteria "Patients with				HIPEC due to death before
	histologically proven peritoneal	and an inflow temperature of			surgery, development of
	metastases of colorectal	41°C to 42°C. As soon as the			liver or lung metastases,
	adenocarcinoma or positive	temperature in the abdomen			withdrawing consent or the
	cytology of ascites, who were	was stable above 40°C, MMC			detection of primary lung
	diagnosed either at first	was added to the perfusate at a			cancer. 14/54 patients
	presentation or at recurrence of	dose of 17.5 mg/m2 followed			never started adjuvant
	colorectal adenocarcinoma."	by 8.8 mg/m2 every 30			chemotherapy after
	Evolution esiteria "Oirne of	minutes. The total dose was			cytoreduction followed by
	Exclusion criteria "Signs of	limited to 70 mg at maximum. If			HIPEC.
	distant metastases (liver, lung)	the core temperature exceeded			
	on computed tomography (CT)	39°C, the inflow temperature			
	scan of abdomen and chest x-	was reduced. After 90 minutes,			
	ray were allowed. Patients had	the perfusion fluid was drained			

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	to be younger than 71 years and fit for major surgery (normal bone marrow indices, and normal renal and liver functions). Initially, patients who had received fluorouracil (FU) within 12 months before random assignment were excluded. In the first year of the study, an amendment to the protocol was made to allow inclusion of these patients."	temporary colostomy was made in most cases if the rectum was resected. A draining gastrostomy and transgastric jejunal feeding tube were inserted. The outflow catheters were used for postoperative drainage of the			

FINAL

Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
		progression or intolerable toxicity."			
Full citation Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G., van Tinteren, H., 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer, Annals of Surgical Oncology, 15, 2426-32, 2008 Ref Id 493134 Country/ies where the study was carried out Study type 8 year follow up of Verwaal 2003 for study details. Aim of the study	Sample size Characteristics Inclusion criteria Exclusion criteria	Interventions	Details Follow up: All patients were seen at the outpatient clinic once every 3 months for 2 years, every 6 months until 5 years after the randomization and once a year thereafter. Outcomes: disease specific survival (time from randomisation to death from any cause), progression free survival	Results Progression free survival, months (median) CRS+HIPEC+SCT= 12.6 Standard= 7.7 p-value= 0.020	Limitations Other information "During the followup, one patient was crossed over from the control arm to the HIPEC arm due to recurrence of the disease. This was at 30 months after randomization. For surviva this patient was censored the moment of the "cross- over"."
Study dates					

ALT: Alanine transaminase; ANC: absolute neutrophil count; AST: aspartate transaminase; CHIP: intraperitoneal chemohyperthermia; CI: confidence interval; CRS: cytoreductive surgery; CT; computed tomography; FU: Fluorouracil/5-FU; HIPEC: hyperthermic intraperitoneal chemotherapy; HR: hazard ratio; IQR: interquartile range; IV:

intravenous; MMC: mitomycin C; N: number; NOS: not otherwise specified; PC: peritoneal carcinomatosis; R0: complete resection: R1: microscopic tumour tissue present at

resection margin; R2: macroscopic tumour tissue present at resection margin; RCT: randomised controlled trial; ROBINS-I: a tool for assessing risk of bias in non-randomised

studies; SCT: systemic chemotherapy/systemic anti-cancer therapy; ULN: upper limit of normal; WHO: World Health Organization


1 Appendix E – Forest plots

2 Forest plots for review question: What is the optimal combination and sequence

- 3 of local and systemic treatments in patients presenting with metastatic
- 4 colorectal cancer isolated in the peritoneum?

5 Figure 2: Comparison 1 – cytoreductive surgery (CRS) with hyperthermic

6 7 intraperitoneal chemotherapy (HIPEC) versus CRS +/- systemic anti-cancer therapy (SACT) – overall survival



Favours CRS + HIPEC Favours surgery +/- SACT
 CI: confidence interval; CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; IV:
 inverse variance; SACT: systemic anti-cancer therapy; SE: standard error

Figure 3: Comparison 1 – cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) versus CRS +/- systemic anti-cancer therapy (SACT) – treatment-related mortality

	CRS + HIPEC Surgery +/- Se		SCT	Risk Ratio		Risk	Ratio				
Study or Subgroup	Events	Total	Events	Total	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl				
1.5.3 30-day mortality - CRS	+ HIPEC +	oxalipl	atin vs CRS	alone							
PRODIGE 7 [Quenet 2018]	2	133	2	132	0.99 [0.14, 6.94]			└──			
						0.005	n'1	1 1	ά		


14
 15 CI: confidence interval; CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; M-H:
 16 Mantel–Haenszel; SACT: systemic anti-cancer therapy

Figure 4: Comparison 1 – cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) versus CRS +/- systemic anti-cancer therapy (SACT) – treatment-related mortality

	CRS + HI	PEC	Surgery +/-	SACT	Peto Odds Ratio		Peto Od	lds Ratio			
Study or Subgroup	Events	Total	Events	Total	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI					
1.6.4 30-day mortali	ty - CRS + H	IIPEC +	SACT vs sur	rgery + S	ACT						
Verwaal 2003	4	48	0	51	8.39 [1.15, 61.51]			+			
						_					
						0.005	0.1	i 10	200		
							Favours CRS + HIPEC	Favours surgery +/- SACT			

20
 21 CI: confidence interval; CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; SACT:
 22 systemic anti-cancer therapy

Figure 5: Comparison 1 – cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) versus CRS +/- systemic anti-cancer therapy (SACT) – grade 3 or 4 complications




26

FINAL Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

- 1 2 CI: confidence interval; CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; M-H:
- Mantel-Haenszel; SACT: systemic anti-cancer therapy

3 Figure 6: Comparison 2 – systemic anti-cancer therapy (SACT) versus supportive care 4 overall survival



5 6 7 CI: confidence interval; CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; IV: inverse variance; SACT: systemic anti-cancer therapy; SE: standard error

1 Appendix F – GRADE tables

2 GRADE tables for review question: What is the optimal combination and sequence of local and systemic treatments in 3 patients presenting with metastatic colorectal cancer isolated in the peritoneum?

4 Table 5: Clinical evidence profile for profile for comparison 1: cytoreductive surgery (CRS) with hyperthermic intraperitoneal 5 chemotherapy (HIPEC) + SACT versus CRS +/- systemic anti-cancer therapy (SACT)

Quality	assessment						No of patie	1	Effect			
No of studie s	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	CRS + HIPEC + SACT	CRS +/- SACT	Relative (95% CI)	Absolute	Quality	Importance
Progres	ssion-free surviv	al										
0	no evidence available	-	-	-	-	-	-	-	-	-	-	CRITICAL
Overall	survival (mediar	n follow up o	of 21.6 months), e	vent is death fro	m any cause -	CRS + HIPEC + SA	CT versus s	urgery + SAC1				
1	randomised trials	serious risk of bias ¹	no serious inconsistency	serious ²	serious ³	none	24/54 (44.4%)	31/51 (60.7%)	HR 0.55 (0.32 to 0.95)	At 2 years surgery + SACT 60.7% ^a , CRS + HIPEC + SACT 76.0% (62.2% to 85.2%)	VERY LOW	CRITICAL
Overall	survival (mediar	n follow up 6	63.8 months), ever	nt is death from	any cause – CF	RS + HIPEC + oxali	platin vs CR	S alone				
1	randomised trials	serious ⁴	no serious inconsistency	no serious indirectness	serious ³	none	133	132	HR 1.00 (0.73 to 1.37)	Not calculable⁵	LOW	CRITICAL
Overall	quality of life											
0	no evidence available	-	-	-	-	-	-	-	-	-	-	CRITICAL

Quality	assessment						No of patie	ents	Effect			
No of studie s	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	CRS + HIPEC + SACT	CRS +/- SACT	Relative (95% CI)	Absolute	Quality	Importance
1	randomised trials	serious ⁴	no serious inconsistency	no serious indirectness	serious ³	none	2/133 (1.5%)	2/132 (1.5%)	RR 0.99 (0.14 to 6.94)	990 fewer per 1000 (from 2410 fewer to 4390 more)	LOW	IMPORTANT
30-day	treatment-related	mortality -	CRS + HIPEC + S	ACT versus sur	gery + SACT							
1	randomised trials	serious risk of bias ¹	no serious inconsistency	serious ²	serious ³	none	4/48 (8.3%)	0/51 (0%)	Peto OR 8.39 (1.15 to 61.51)	-	VERY LOW	IMPORTANT
Grade 3	or 4 complication	ons - CRS +	HIPEC + oxaliplat	tin versus CRS a	alone							
1	randomised trials	serious ⁴	no serious inconsistency	no serious indirectness	serious ³	none	32/133 (24.1%)	18/132 (13.6%)	RR 1.76 (1.04 to 2.98)	136 fewer per 1000 (from 136 fewer to 136 more)	LOW	IMPORTANT

CI: confidence interval; CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; HR: hazard ratio; OR: odds ratio; RR: relative risk; SACT: systemic anti-cancer therapy 1 7/51 patients (14%) in standard arm never started SCT; 12/38 in standard arm did not complete SCT; 5/54 in treatment arm complete CRS + HIPEC; 14/54 never started adjuvant CT after CRS + HIPEC (Verwaal 2003)

2 Quality of evidence was downgraded by 1 due to 18/105 (17%) patients having appendiceal disease (Verwaal 2003)

3 Quality of evidence downgraded by 1 because of imprecision of the effect estimate (< 300 events for dichotomous outcomes or < 400 participants for continuous outcomes).

4 Quality of evidence was downgraded by 1 because the study did not report the event rates (PRODIGE 7)

5 The absolute effect was not calculable because the study did not report the event rates (PRODIGE 7)

a The absolute risk at 2 years in the control group taken from Verwaal 2003

10 Table 6: Clinical evidence profile for comparison 2: Systemic anti-cancer therapy (SACT) versus supportive care

Quality assessment						No of patients		Effect				
No of studie s	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	SACT	Suppo rtive care	Relative (95% CI)	Absolut e	Qualit y	Importance
Progression free survival												
0	no evidence available	-	-	-	-	-	-	-	-	-	-	CRITICAL

32

Optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum

Quality assessment						No of patients		Effect				
No of studie s	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	SACT	Suppo rtive care	Relative (95% CI)	Absolut e	Qualit y	Importance
50-mont therapy	th overall survival,	event is dea	ath from any cause,	controlled for s	ex, age, comort	oidity, primary tumo	our location and sys	temic ther	apy - Chemo	otherapy onl	y versus r	no systemic
1	observational studies	serious ¹	no serious inconsistency	serious ²	serious ³	none	49/56 (87.5%)	90/94 (95.7%)	HR 0.51 (0.35 to 0.74)	At 50 months no systemic treatment 4.3% ^a , CT only 20.1% (9.7% to 33.2%)	VERY LOW	CRITICAL
	th overall survival, c therapy	event is dea	ath from any cause,	controlled for s	ex, age, comort	oidity, primary tumo	our location and sys	temic ther	apy - Chemo	otherapy + b	evacizum	ab versus no
1	observational studies	serious ¹	no serious inconsistency	serious ²	serious ³	none	31/36 (86.1%)	90/94 (95.7%)	HR 0.35 (0.22 to 0.56)	At 50 months no systemic treatment 4.3% ^a , CT + Bevacizu mab 33.2% (17.2% to 50%)	VERY LOW	CRITICAL
Overall	quality of life											
D	no evidence available	-	-	-	-	-	-	-	-	-	-	CRITICAL
Freatme	ent-related mortality	y										
)	no evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTAN T
Any gra	de 3/4 complicatio	ns										
)	no evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTAN T
	of hospital stay											MARCER
)	no evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTAI T

- CI: confidence interval; CT: chemotherapy; HR: hazard ratio; SACT: systemic anti-cancer therapy
- 1 Quality of evidence was downgraded by 1 as differences in characteristics between groups at baseline, deviations from intended protocol (van Oudheusden 2015)
- 12345 2 Quality of evidence downgraded by 1 due to proportion of patients having other distant metastases (van Oudheusden 2015)
 - 3 Quality of evidence downgraded by 1 because of imprecision of the effect estimate (< 300 events for dichotomous outcomes or < 400 participants for continuous outcomes)
 - a The absolute risk at 50 months in the control group taken from van Oudheusden (2015)

1 Appendix G – Economic evidence study selection

2 Economic evidence study selection for review question: What is the optimal

- 3 combination and sequence of local and systemic treatments in patients
- 4 presenting with metastatic colorectal cancer isolated in the peritoneum?
- 5 A global search of economic evidence was undertaken for all review questions in this
- 6 guideline. See Supplement 2 for further information.

1 Appendix H – Economic evidence tables

2 Economic evidence tables for review question: What is the optimal combination and

- 3 sequence of local and systemic treatments in patients presenting with metastatic
- 4 colorectal cancer isolated in the peritoneum?
- 5 No economic evidence was identified which was applicable to this review question.

1 Appendix I – Economic evidence profiles

2 Economic evidence profiles for review question: What is the optimal combination

- and sequence of local and systemic treatments in patients presenting with
 metastatic colorectal cancer isolated in the peritoneum?
- 5 No economic evidence was identified which was applicable to this review question.

1 Appendix J – Economic analysis

2 Economic evidence analysis for review question: What is the optimal

- 3 combination and sequence of local and systemic treatments in patients
- 4 presenting with metastatic colorectal cancer isolated in the peritoneum?
- 5 No economic analysis was conducted for this review question.

6

1 Appendix K – Excluded studies

2 Excluded clinical studies for review question: What is the optimal combination

- and sequence of local and systemic treatments in patients presenting with
- 4 metastatic colorectal cancer isolated in the peritoneum?

5 **Table 7: Excluded studies and reasons for their exclusion**

Study	Reason for exclusion
Akbarov, E. T., Navruzov, S. N., Abdujapparov, S. B., Hakimov, A. M., Khudayarov, S. S., Islamov, K. J., Babakulob, H. B., Turaev, G. Kh, Use targeted therapy with endolymphatic chemotherapy in peritoneal carcinomatosis of colorectal cancer, Annals of Oncology, Conference, 2009	Full text is an abstract
Baratti, D., Kusamura, S., Iusco, D., Bonomi, S., Grassi, A., Virzi, S., Leo, E., Deraco, M., Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: A two-center study of 101 patients, Diseases of the Colon and Rectum, 57, 858-868, 2014	Cohort study design not relevant; RCT evidence available
Baratti, D., Kusamura, S., Pietrantonio, F., Guaglio, M., Niger, M., Deraco, M., Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review, Critical Reviews in Oncology/Hematology, 100, 209-222, 2016	Systematic review - studies assessed individually
Bloemendaal, A. L. A., Verwaal, V. J., van Ruth, S., Boot, H., Zoetmulder, F. A. N., Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective study, European Journal of Surgical Oncology, 31, 1145-1151, 2005	Not comparative - analyses the control arm from Verwaal 2003
Braam, H. J., Boerma, D., Wiezer, M. J., van Ramshorst, B., Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment, European Journal of Surgical Oncology, 39, 988-93, 2013	Comparison not relevant - one- stage primary tumour resection HIPEC versus two-stage procedure
Cao, C., Yan, T. D., Black, D., Morris, D. L., A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin, Annals of Surgical Oncology, 16, 2152-65, 2009	Systematic review - studies assessed individually
Cashin, P. H., Mahteme, H., Spang, N., Syk, I., Frodin, J. E., Torkzad, M., Glimelius, B., Graf, W., Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial, European Journal of Cancer, 53, 155-162, 2016	Intervention not relevant, did no include HIPEC
Cashin, P. H., Mahteme, H., Syk, I., Frodin, J. E., Glimelius, B., Graf, W., Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases, European Journal of Surgical Oncology., 2018	Intervention not relevant, did no include HIPEC
Cashin, P. H., Graf, W., Nygren, P., Mahteme, H., Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumour markers: An observational cohort study, Annals of Surgery, 256, 1078-1083, 2012	Cohort study design not relevant; RCT evidence available

Cashin, P. H., Graf, W., Nygren, P., Mahteme, H., Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: Prognosis and treatment of recurrences in a cohort study, European Journal of Surgical Oncology, 38, 509-515, 2012	Comparison not relevant - CRS HIPEC versus CRS sequential postoperative intraperitoneal CT
Cashin, P. H., Graf, W., Nygren, P., Mahteme, H., Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: A case- control study, Annals of Oncology, 23, 647-652, 2012	Comparison not relevant - HIPEC versus normothermic sequential postoperative intraperitoneal chemotherapy (SPIC)
Cavaliere, F., Perri, P., Di Filippo, F., Giannarelli, D., Botti, C., Cosimelli, M., Tedesco, M., Principi, F., Laurenzi, L., Cavaliere, R., Treatment of peritoneal carcinomatosis with intent to cure, Journal of Surgical Oncology, 74, 41-4, 2000	Not comparative
Ceelen, W., Van Nieuwenhove, Y., Putte, D. V., Pattyn, P., Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis, Annals of Surgical Oncology, 21, 3023-3028, 2014	Not comparative
Chia, C. S., Seshadri, R. A., Kepenekian, V., Vaudoyer, D., Passot, G., Glehen, O., Survival outcomes after Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: A systematic review, Pleura and Peritoneum, 1, 67-77, 2016	Population not relevant - patients had gastric cancer
Chua, T. C., Morris, D. L., Saxena, A., Esquivel, J., Liauw, W., Doerfer, J., Germer, C. T., Kerscher, A. G., Pelz, J. O. W., Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: A multicenter study, Annals of Surgical Oncology, 18, 1560-1567, 2011	Cohort study design not relevant; RCT evidence available
Chua, T. C., Quinn, L. E., Zhao, J., Morris, D. L., Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases, Journal of Surgical Oncology, 108, 81-88, 2013	Comparison not relevant - primary CRS versus iterative CRS
Devilee, R, Simkens, G, Oudheusden, T, Rutten, H, Creemers, G, Tije, B, Nieuwenhuijzen, G, Hingh, I, Timing of systemic treatment in patients undergoing cytoreductive surgery and HIPEC for peritoneal metastases of colorectal origin, Annals of surgical oncology., 23, S80-s81, 2016	Full text is an abstract
Devilee, R. A., Simkens, G. A., van Oudheusden, T. R., Rutten, H. J., Creemers, G. J., ten Tije, A. J., de Hingh, I. H., Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy, Annals of Surgical Oncology, 23, 2841-2848, 2016	Cohort study design not relevant; RCT evidence available
Elias, D., Delperro, J. R., Sideris, L., Benhamou, E., Pocard, M., Baton, O., Giovannini, M., Lasser, P., Treatment of peritoneal carcinomatosis from colorectal cancer: Impact of complete cytoreductive surgery and difficulties in conducting randomized trials, Annals of Surgical Oncology, 11, 518-521, 2004	Intervention not relevant, did not include HIPEC
Elias, D., Blot, F., Elotmany, A., Antoun, S., Lasser, P., Boige, V., Rougier, P., Ducreux, M., Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy, Cancer, 92, 71-76, 2001	Cohort study design not relevant; RCT evidence available

Cohort study design not relevant; RCT evidence available
Cohort study design not relevant; RCT evidence available
Summaries of previously completed cohort studies and trials
Cohort study design not relevant; RCT evidence available
Cohort study design not relevant; RCT evidence available
Systematic review - studies assessed individually
Cohort study design not relevant; RCT evidence available
Comparison not relevant - patients with peritoneal carcinomatosis CRC (pcCRC) versus non-pcCRC
< 25% of patients in each included trial had peritoneal metastases

Gervais, M. K., Dube, P., McConnell, Y., Drolet, P., Mitchell, A., Sideris, L., Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer, Journal of Surgical Oncology, 108, 438-443, 2013 Cohort study design not relevant; RCT evidence available Giehen, O., Cotte, E., Schreiber, V., Sayag-Beaujard, A. C., Vignal, J., Gliy, F. N., Intrapertoneal chemothyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin, British Journal of Surgery, 91, 747-754, 2004 Cohort study design not relevant; RCT evidence available Giehen, O., Kwiatkowski, F., Sugarbaker, P. H., Ellas, D., Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., Gutman, M., Tentes, A. A. K., Cohort study design not relevant; RCT evidence available Gorez-Portila, A., Shen, P., Deraco, M., Rat, P., Gilly, F. N., Cytoreductive Surgery Comited with peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study. Journal of Clinical Oncology, 22, 3264-3292, 2004 Cohort study design not relevant; RCT evidence available Glockzin, G., Gerken, M., Lang, S. A., Klinkhammer-Schalke, M., Trestment-related morbidity and toxicity of CRS and oxaliplatin- based HIPEC Coompared to a mitomycin and doxorubicin-based HIPEC Cooson to the anitomycin and doxorubicin-based HIPEC Cooson to the anitomycin and doxorubicin-based HIPEC Cooson of to Benitoneal carcinomatosis: a matched-pair analysis, Journal of Surgical Oncology, 107, 574-8, 2013 Cohort study design not relevant; RCT evidence available Gere, D., Souadka, A., Faron, M., Cloutier, A. S., Viana, B., Honore, C., Dumonti, F., Elias, D., Extent of Colorectal arcarinomatosis		
Vignal, J., Gilly, F. N., Intraperitoneal chemotyperthermia and atempted cyboreductive surgery in patients with peritoneal acarinomatosis of colorectal origin, British Journal of Surgery, 91, 747-754, 2004 relevant; RCT evidence available Glehen, O., Kwiatkowski, F., Sugarbaker, P. H., Elias, D., Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cormer, E. A., De Simone, M., Barone, R., Yonemura, Y., Cormer, E. A., De Simone, M., Barone, R., Yonemura, Y., Cormer, F., Quenet, F., Gutman, M., Tentes, A. A. K., Lorimier, G., Bernard, J. L., Bereder, J. M., Porcheron, J., Gomez-Portilla, A., Shen, P., Deraco, M., Rat, P., Gilly, F. N., Cytoreductive Surgery Combined with Peritoperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study, Journal of Clinical Oncology, 22, 3284-3292, 2004 Cohort study design not relevant; RCT evidence available Glockzin, G., Gerken, M., Lang, S. A., Klinkhammer-Schalke, M., Piso, P., Schlitt, H. J., Oxaliplatin-based versus irinotecan-based Hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: A retrospective analysis, BMC Cancer, 14 (1) (no pagination), 2014 Cohort study design not relevant; RCT evidence available Goere, D., Souadka, A., Faron, M., Cloutier, A. S., Viana, B., Othorosci, S., Dumont, F., Elias, D., Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Dees Not Offer Survival Benefit A. Comparative Study, Annals of Surgical Oncology, 22, 2958-2964, 2015 Cohort study design not relevant; RCT evidence available Grass, F., Vuagniaux, A., Teixeira-Farinha, H., Lehmann, K., Demartinea, N., Hubmer, M., Systematic review or pressurized intraperitone	Sideris, L., Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer, Journal of	relevant; RCT evidence
Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., Gutman, M., Tentes, A. A. K., Lorimier, G., Bernard, J. L., Bereder, J. M., Porcheron, J., Gomez-Portilla, A., Shen, P., Deraco, M., Rat, P., Gilly, F. N., Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study, Journal of Clinical Oncology, 22, 3284-3292, 2004 Glockzin, G., Gerken, M., Lang, S. A., Klinkhammer-Schalke, M., Piso, P., Schlitt, H. J., Oxaljinalin-based versus irinotecan-based hyperthernic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: A retrospective analysis, BMC Cancer, 14 (1) (no pagination), 2014 Glockzin, G., von Breitenbuch, P., Schlitt, H. J., Piso, P., Treatment-related morbidity and toxicity of CRS and oxaliplatin- based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis, Journal of Surgical Oncology, 107, 574-8, 2013 Goere, D., Souadka, A., Faron, M., Cloutier, A. S., Viana, B., Honore, C., Dumont, F., Elias, D., Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study, Annals of Surgical Oncology, 22, 2958-2964, 2015 Grass, F., Vuagniaux, A., Teixeira-Farinha, H., Lehmann, K., Demartines, N., Hubner, M., Systematic review of pressurized intraperitoneal carcinomatosis, British Journal of Surgery, 104, 669-678, 2017 He, T., Chen, Z., Xing, C., Cytoreductive surgery combined with intraperitoneal carcinomatosis, British Journal of Surgical Oncology, 109, 276-38, 2014 Huang, C. Q., Feng, J. P., Yang, X. J., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal carcinomatosis from colorectal cancer: A camparative study, Journal of Surgical Oncology, 109, 277-532, 2014 Huang, C. Q., Min, Y., Wang, S. Y., Yang, X. J., Li, Y., Xiong, Systema	Vignal, J., Gilly, F. N., Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin, British Journal of Surgery,	relevant; RCT evidence
Piso, P., Schlitt, H. J., Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: A retrospective analysis, BMC Cancer, 14 (1) (no pagination), 2014relevant; RCT evidence availableGlockzin, G., von Breitenbuch, P., Schlitt, H. J., Piso, P., Treatment-related morbidity and toxicity of CRS and oxaliplatin- based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis, Journal of Surgical Oncology, 107, 574-8, 2013Cohort study design not relevant; RCT evidence availableGoere, D., Souadka, A., Faron, M., Cloutier, A. S., Viana, B., Honore, C., Dumont, F., Elias, D., Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study, Annals of Surgical Oncology, 22, 2958-2964, 2015Cohort study design not relevant; RCT evidence availableGrass, F., Vuagniaux, A., Teixeira-Farinha, H., Lehmann, K., Demartines, N., Hubner, M., Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis, British Journal of Surgery, 104, 669-678, 2017Intervention not relevant - pressurized intraperitoneal demotherapy in the treatment of colorectal cancer: A comparative study, Journal of Surgical Oncology, 109, 527-532, 2014Systematic review - studies assessed individuallyHuang, C. Q., Feng, J. P., Yang, X. J., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal carcinomatosis from colorectal carce: A case-control study from a Chinese center, Journal of Surgical Oncology, 109, 730-739, 2014Cohort study design not relevant; RCT evidence	Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., Gutman, M., Tentes, A. A. K., Lorimier, G., Bernard, J. L., Bereder, J. M., Porcheron, J., Gomez-Portilla, A., Shen, P., Deraco, M., Rat, P., Gilly, F. N., Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional	relevant; RCT evidence
Treatment-related morbidity and toxicity of CRS and oxaliplatin- based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis, Journal of Surgical Oncology, 107, 574-8, 2013relevant; RCT evidence availableGoere, D., Souadka, A., Faron, M., Cloutier, A. S., Viana, B., Honore, C., Dumont, F., Elias, D., Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study, Annals of Surgical Oncology, 22, 2958-2964, 2015Cohort study design not relevant; RCT evidence availableGrass, F., Vuagniaux, A., Teixeira-Farinha, H., Lehmann, K., Demartines, N., Hubner, M., Systematic review of pressurized intraperitoneal carcinomatosis, British Journal of Surgery, 104, 669-678, 2017Intervention not relevant - pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis, British Journal of Surgery, 104, 669-678, 2017Intervention not relevant - pressurized intraperitoneal aerosol chemotherapy in the treatment of colorectal and Experimental Medicine, 9, 20562-20570, 2016Systematic review - studies assessed individuallyHompes, D., D'Hoore, A., Wolthuis, A., Fieuws, S., Mirck, B., Bruin, S., Verwaal, V., The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study, Journal of Surgical Oncology, 109, 527-532, 2014Cohort study design not relevant; RCT evidence availableHuang, C. Q., Feng, J. P., Yang, X. J., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center, Journal of Surgical Oncology, 109, 730-739, 2014 </td <td>Piso, P., Schlitt, H. J., Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: A retrospective analysis, BMC Cancer, 14 (1) (no</td> <td>relevant; RCT evidence</td>	Piso, P., Schlitt, H. J., Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: A retrospective analysis, BMC Cancer, 14 (1) (no	relevant; RCT evidence
 Honore, C., Dumont, F., Elias, D., Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study, Annals of Surgical Oncology, 22, 2958-2964, 2015 Grass, F., Vuagniaux, A., Teixeira-Farinha, H., Lehmann, K., Demartines, N., Hubner, M., Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis, British Journal of Surgery, 104, 669-678, 2017 He, T., Chen, Z., Xing, C., Cytoreductive surgery combined with intraperitoneal chemotherapy in the treatment of colorectal peritoneal metastasis: A meta-analysis, International Journal of Clinical and Experimental Medicine, 9, 20562-20570, 2016 Hompes, D., D'Hoore, A., Wolthuis, A., Fieuws, S., Mirck, B., Bruin, S., Verwaal, V., The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study, Journal of Surgical Oncology, 109, 527-532, 2014 Huang, C. Q., Feng, J. P., Yang, X. J., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center, Journal of Surgical Oncology, 109, 730-739, 2014 Huang, C. Q., Min, Y., Wang, S. Y., Yang, X. J., Liu, Y., Xiong, Systematic review - studies 	Treatment-related morbidity and toxicity of CRS and oxaliplatin- based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis, Journal of Surgical Oncology, 107, 574-8,	relevant; RCT evidence
 Demartines, N., Hubner, M., Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis, British Journal of Surgery, 104, 669-678, 2017 He, T., Chen, Z., Xing, C., Cytoreductive surgery combined with intraperitoneal chemotherapy in the treatment of colorectal peritoneal metastasis: A meta-analysis, International Journal of Clinical and Experimental Medicine, 9, 20562-20570, 2016 Hompes, D., D'Hoore, A., Wolthuis, A., Fieuws, S., Mirck, B., Bruin, S., Verwaal, V., The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study, Journal of Surgical Oncology, 109, 527-532, 2014 Huang, C. Q., Feng, J. P., Yang, X. J., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center, Journal of Surgical Oncology, 109, 730-739, 2014 Huang, C. Q., Min, Y., Wang, S. Y., Yang, X. J., Liu, Y., Xiong, Systematic review - studies 	Honore, C., Dumont, F., Elias, D., Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study,	relevant; RCT evidence
 intraperitoneal chemotherapy in the treatment of colorectal peritoneal metastasis: A meta-analysis, International Journal of Clinical and Experimental Medicine, 9, 20562-20570, 2016 Hompes, D., D'Hoore, A., Wolthuis, A., Fieuws, S., Mirck, B., Bruin, S., Verwaal, V., The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study, Journal of Surgical Oncology, 109, 527-532, 2014 Huang, C. Q., Feng, J. P., Yang, X. J., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center, Journal of Surgical Oncology, 109, 730-739, 2014 Huang, C. Q., Min, Y., Wang, S. Y., Yang, X. J., Liu, Y., Xiong, Systematic review - studies 	Demartines, N., Hubner, M., Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis, British Journal of Surgery,	pressurized intraperitoneal
Bruin, S., Verwaal, V., The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study, Journal of Surgical Oncology, 109, 527-532, 2014relevant; RCT evidence availableHuang, C. Q., Feng, J. P., Yang, X. J., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center, Journal of Surgical Oncology, 109, 730-739, 2014Cohort study design not relevant; RCT evidence availableHuang, C. Q., Min, Y., Wang, S. Y., Yang, X. J., Liu, Y., Xiong,Systematic review - studies	intraperitoneal chemotherapy in the treatment of colorectal peritoneal metastasis: A meta-analysis, International Journal of	
surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center, Journal of Surgical Oncology, 109, 730-739, 2014relevant; RCT evidence availableHuang, C. Q., Min, Y., Wang, S. Y., Yang, X. J., Liu, Y., Xiong,Systematic review - studies	Bruin, S., Verwaal, V., The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study, Journal of Surgical Oncology, 109,	relevant; RCT evidence
	surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center,	relevant; RCT evidence

hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: A systematic review and meta-analysis of current evidence, Oncotarget, 8, 55657-55683, 2017	
Huang, C. Q., Yang, X. J., Yu, Y., Wu, H. T., Liu, Y., Yonemura, Y., Li, Y., Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: A phase II study from a Chinese Center, PLoS ONE, 9 (9) (no pagination), 2014	Not comparative
Klaver, C. E. L., Groenen, H., Morton, D. G., Laurberg, S., Bemelman, W. A., Tanis, P. J., Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines, Colorectal Disease, 19, 224-236, 2017	Study design not relevant - systematic review of guidelines
Klaver, Y. L. B., Leenders, B. J. M., Creemers, G. J., Rutten, H. J. T., Verwaal, V. J., Lemmens, V. E. P. P., De Hingh, I. H. J. T., Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin, American Journal of Clinical Oncology: Cancer Clinical Trials, 36, 157-161, 2013	Comparison not relevant - compares different systemic treatments
Kobayashi, H., Kotake, K., Sugihara, K., Outcomes of surgery without HIPEC for synchronous peritoneal metastasis from colorectal cancer: Data from a multi-center registry, International Journal of Clinical Oncology, 19, 98-105, 2014	Cohort study design not relevant; RCT evidence available
Kobayashi, H., Kotake, K., Sugihara, K., Impact of surgical resection of synchronous peritoneal metastasis from colorectal cancer: A propensity scorematched analysis, Diseases of the Colon and Rectum, 61 (5), e226, 2018	Full text is an abstract
Kok, N. F., de Hingh, I. H., Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin, The British journal of surgery, 104, 313-315, 2017	Cohort study design not relevant; RCT evidence available
Kuijpers, A. M., Mehta, A. M., Boot, H., Van leerdam, M. E., Hauptmann, M., Aalbers, A. G., Verwaal, V. J., Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, Annals of Oncology, 25, 864-869, 2014	Cohort study design not relevant; RCT evidence available
Lam, J. Y., McConnell, Y. J., Rivard, J. D., Temple, W. J., Mack, L. A., Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis, American Journal of Surgery, 210, 424-30, 2015	Comparison not relevant - HIPEC EPIC versus HIPEC alone
Lee, L., Alie-Cusson, F., Dube, P., Sideris, L., Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis, Journal of Surgical Oncology, 116, 236-243, 2017	Cohort study design not relevant; RCT evidence available
Maciver, A. H., Lee, N., Skitzki, J. J., Boland, P. M., Francescutti, V., Cytoreduction and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) in colorectal cancer: Evidence-based review of patient selection and treatment algorithms, European Journal of Surgical Oncology, 43, 1028-1039, 2017	Narrative review

Maggiori, L., Goere, D., Viana, B., Tzanis, D., Dumont, F., Honore, C., Eveno, C., Elias, D., Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent?: A case-control study, Annals of Surgery, 258, 116-121, 2013	Cohort study design not relevant; RCT evidence available
Mahteme, H., Hansson, J., Berglund,, Pahlman, L., Glimelius, B., Nygren, P., Graf, W., Improved survival in patients with peritoneal metastases from colorectal cancer: A preliminary study, British Journal of Cancer, 90, 403-407, 2004	Population not relevant, only 8/18 patients had peritoneal metastases
Maillet, M., Glehen, O., Lambert, J., Goere, D., Pocard, M., Msika, S., Passot, G., Elias, D., Eveno, C., Sabate, J. M., Lourenco, N., Andre, T., Gornet, J. M., Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study, Annals of Surgical Oncology, 23, 863-869, 2016	Cohort study design not relevant; RCT evidence available
McConnell, Y. J., Mack, L. A., Francis, W. P., Ho, T., Temple, W. J., HIPEC+EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy, Journal of Surgical Oncology, 107, 591-6, 2013	Comparison not relevant - HIPEC EPIC versus HIPEC alone
Mirnezami, R., Mehta, A. M., Chandrakumaran, K., Cecil, T., Moran, B. J., Carr, N., Verwaal, V. J., Mohamed, F., Mirnezami, A. H., Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone, British Journal of Cancer, 111, 1500-1508, 2014	Systematic review; studies assessed individually
Mirnezami, R., Moran, B. J., Harvey, K., Cecil, T., Chandrakumaran, K., Carr, N., Mohamed, F., Mirnezami, A. H., Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases, World Journal of Gastroenterology, 20, 14018-32, 2014	Systematic review - studies assessed individually
Nadler, A., McCart, J. A., Govindarajan, A., Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy, Clinics in Colon & Rectal Surgery, 28, 234-46, 2015	Systematic review - studies assessed individually
Park, S. Y., Choi, G. S., Park, J. S., Kim, H. J., Yang, C. S., Kim, J. G., Kang, B. W., Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case-Control Study from a Single Center, Annals of Surgical Oncology, 23, 2266-2273, 2016	Cohort study design not relevant; RCT evidence available
Passot, G., Vaudoyer, D., Cotte, E., You, B., Isaac, S., Noel Gilly, F., Mohamed, F., Glehen, O., Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis, Annals of Surgery, 256, 125-129, 2012	Cohort study design not relevant; RCT evidence available
Passot, G., You, B., Boschetti, G., Fontaine, J., Isaac, S., Decullier, E., Maurice, C., Vaudoyer, D., Gilly, F. N., Cotte, E., Glehen, O., Pathological response to neoadjuvant chemotherapy: A new prognosis tool for the curative management of peritoneal colorectal carcinomatosis, Annals of Surgical Oncology, 21, 2608-2614, 2014	Cohort study design not relevant; RCT evidence available
Pelz, J. O. W., Chua, T. C., Esquivel, J., Stojadinovic, A., Doerfer, J., Morris, D. L., Maeder, U., Germer, C., Kerscher, A. G., Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the	No case mix adjustments

retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin, BMC Cancer, 10, 689, 2010	
Pestieau, S. R., Sugarbaker, P. H., Ota, D. M., Treatment of primary colon cancer with peritoneal carcinomatosis: Comparison of concomitant versus. delayed management, Diseases of the Colon and Rectum, 43, 1341-1348, 2000	Cohort study design not relevant; RCT evidence available
Piso, P., Koller, M., Arnold, D., J. Schlitt H, Glockzin, G., Multimodality treatment of colorectal peritoneal metastasis with perioperative systemic chemotherapy, cytoreductive surgery (CRS), and HIPEC: First safety results of the COMBATAC trial, Journal of Clinical Oncology. Conference, 32, 2014	Full text is an abstract; not comparative
Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M., Chua, T., Pelz, J., Baratti, D., Baumgartner, J. M., Berri, R., Bretcha-Boix, P., Deraco, M., Flores-Ayala, G., Glehen, O., Gomez-Portilla, A., Gonzalez-Moreno, S., Goodman, M., Halkia, E., Kusamura, S., Moller, M., Passot, G., Pocard, M., Salti, G., Sardi, A., Senthil, M., Spiliotis, J., Torres-Melero, J., Turaga, K., Trout, R., The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery, Journal of Surgical Oncology, 110, 779-785, 2014	Cohort study design not relevant; RCT evidence available
Rivard, J. D., McConnell, Y. J., Temple, W. J., Mack, L. A., Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: Are we excluding patients who may benefit?, Journal of Surgical Oncology, 109, 104-109, 2014	Not comparative
Rovers, K. P., Simkens, G. A., Punt, C. J., van Dieren, S., Tanis, P. J., de Hingh, I. H., Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review, Critical Reviews in Oncology/Hematology, 114, 53-62, 2017	Systematic review - studies assessed individually
Sammartino, P., Sibio, S., Biacchi, D., Cardi, M., Accarpio, F., Mingazzini, P., Rosati, M. S., Cornali, T., Di Giorgio, A., Prevention of peritoneal metastases from colon cancer in high- risk patients: Preliminary results of surgery plus prophylactic HIPEC, Gastroenterology Research and Practice, (no pagination), 2012	Cohort study design not relevant; RCT evidence available
Sammartino, P., Sibio, S., Biacchi, D., Cardi, M., Mingazzini, P., Rosati, M. S., Cornali, T., Sollazzo, B., Atta, J. M., Di Giorgio, A., Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases, International Journal of Colorectal Disease, 29, 1081-1089, 2014	Cohort study design not relevant; RCT evidence available
Scaringi, S., Leo, F., Canonico, G., Batignani, G., Ficari, F., Tonelli, F., The role of cytoreductive surgery alone for the treatment of peritoneal carcinomatosis of colorectal origin. A retrospective analysis with regard to multimodal treatments, Hepato-Gastroenterology, 56, 650-655, 2009	Not comparative
Shen, P., Stewart, Iv J. H., Levine, E. A., Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Overview and Rationale, Current Problems in Cancer, 33, 125-141, 2009	Narrative review
Shen, P., Stewart, J. H, Levine, E. A., The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer with peritoneal surface disease, Current Problems in Cancer, 33, 154-67, 2009	Not comparative

Ung, L., C. Chua T, L. Morris D, Peritoneal metastases of lower gastrointestinal tract origin: A comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy, Journal of Cancer Research and Clinical Oncology, 139, 1899-1908, 2013	Cohort study design not relevant; RCT evidence available
Ung, L., Chua, T. C., Morris, D. L., Cure for peritoneal metastases? An evidence-based review, ANZ Journal of Surgery, 83, 821-826, 2013	Narrative review
Vaira, M., Cioppa, T., D'Amico, S., De Marco, G., D'Alessandro, M., Fiorentini, G., De Simone, M., Treatment of Peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years, In Vivo, 24, 79-84, 2010	Cohort study design not relevant; RCT evidence available
Vallicelli, C., Cavaliere, D., Catena, F., Coccolini, F., Ansaloni, L., Poiasina, E., Abongwa, H. K., De Simone, B., Alberici, L., Framarini, M., Verdecchia, G. M., Management of peritoneal carcinomatosis from colorectal cancer: review of the literature, International Journal of Colorectal Disease, 29, 895-8, 2014	Narrative review
van Oudheusden, T. R., Braam, H. J., Nienhuijs, S. W., Wiezer, M. J., van Ramshorst, B., Luyer, M. D., Lemmens, V. E., de Hingh, I. H., Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis, Annals of Surgical Oncology, 21, 2621-6, 2014	Cohort study design not relevant; RCT evidence available
Van Oudheusden, T. R., Nienhuijs, S. W., Luyer, M. D., Nieuwenhuijzen, G. A., Lemmens, V. E., Rutten, H. J., De Hingh, I. H., Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review, European Journal of Surgical Oncology, 41, 1269-1277, 2015	Systematic review - studies assessed individually
Verwaal, V. J., Cytoreduction and HIPEC for peritoneal carcinomatosis from colorectal origin: The Amsterdam experience, Acta Chirurgica Belgica, 106, 283-284, 2006	Editorial
Verwaal, V. J., Results of cytoreduction followed by HIPEC in carcinomatosis of colorectal origin, Cancer Treatment & Research, 134, 291-301, 2007	Narrative review
Verzijden, Jcm, Klaver, Ylb, de, Hingh Ignace Hjt, Bleichrodt, Rp, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis in patients with colorectal cancer, Cochrane Database of Systematic Reviews, 2010	Protocol
Waite, K., Youssef, H., The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review, Annals of Surgical Oncology, 24, 705-720, 2017	Systematic review - studies assessed individually
Wu, W., Yan, S., Liao, X., Xiao, H., Fu, Z., Chen, L., Mou, J., Yu, H., Zhao, L., Liu, X., Curative versus palliative treatments for colorectal cancer with peritoneal carcinomatosis: A systematic review and metaanalysis, Oncotarget, 8, 113202-113212, 2017	Systematic review - studies assessed individually
Yan, T. D., Black, D., Savady, R., Sugarbaker, P. H., Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma, Journal of Clinical Oncology, 24, 4011-4019, 2006	Systematic review - studies assessed individually

Yuan, H., Zheng, B., Tu, S., Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer, World Journal of Surgical Oncology, 13, 320, 2015	Population not relevant - mixed population with peritoneal, liver and other liver metastases. Intervention not relevant - not HIPEC
Zani, S., Papalezova, K., Stinnett, S., Tyler, D., Hsu, D., Blazer, lii D. G., Modest advances in survival for patients with colorectal- associated peritoneal carcinomatosis in the era of modern chemotherapy, Journal of Surgical Oncology, 107, 307-311, 2013	Comparison not relevant - received CT pre or post 2003
Zhu, Y., Hanna, N., Boutros, C., Alexander Jr, H. R., Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal metastases, Journal of Gastrointestinal Oncology, 4, 62-71, 2013	Narrative review

1

1 Appendix L – Research recommendations

2 Research recommendations for review question: What is the optimal combination

- 3 and sequence of local and systemic treatments in patients presenting with
- 4 metastatic colorectal cancer isolated in the peritoneum?
- 5 No research recommendations were made for this review question.